Bioactive Peptides

Authored by: Marta Miguel , Blanca Hernández-Ledesma , Rosina López-Fandiño , Isidra Recio

Handbook of Analysis of Active Compounds in Functional Foods

Print publication date:  January  2012
Online publication date:  January  2012

Print ISBN: 9781439815885
eBook ISBN: 9781439815908
Adobe ISBN:




Proteins and peptides from food are essential components of the diet as sources of amino acids. It has been also recognized that dietary proteins and peptides exert many other functionalities in vivo, directly or after hydrolysis. Several biologically active peptides have been identified after hydrolysis of food proteins by digestive enzymes during gastrointestinal transit or by fermentation or ripening during food processing. These bioactive peptides have been defined as specific amino acid sequences that may exhibit regulatory functions in the organism beyond normal and adequate nutrition. Once ingested, they may exert different activities in the major body systems: cardiovascular, digestive, endocrine, immune, and nervous system. Although any food protein from plant or animal origin may act as a precursor of these bioactive peptides, to date, most of the bioactive peptides described and commercially used derive from milk proteins. Research in the field of bioactive peptides has intensified in the past two decades (for recent reviews, see for instance [13]).

 Add to shortlist  Cite

Bioactive Peptides

3.1  Introduction

Proteins and peptides from food are essential components of the diet as sources of amino acids. It has been also recognized that dietary proteins and peptides exert many other functionalities in vivo, directly or after hydrolysis. Several biologically active peptides have been identified after hydrolysis of food proteins by digestive enzymes during gastrointestinal transit or by fermentation or ripening during food processing. These bioactive peptides have been defined as specific amino acid sequences that may exhibit regulatory functions in the organism beyond normal and adequate nutrition. Once ingested, they may exert different activities in the major body systems: cardiovascular, digestive, endocrine, immune, and nervous system. Although any food protein from plant or animal origin may act as a precursor of these bioactive peptides, to date, most of the bioactive peptides described and commercially used derive from milk proteins. Research in the field of bioactive peptides has intensified in the past two decades (for recent reviews, see for instance [13]).

The potential of bioactive peptides to improve consumer’s health is a subject of great interest to the scientific community and the food industry. Different chemical and biological methods have been developed and applied to screen their bioactivity, and in some cases, the postulated effects have also been proved in animal and human studies. In addition, the identification and characterization of these peptides is performed using different analytical techniques namely, electrophoresis, chromatography, immunochemical methods, and mass spectrometry in its different modes. A detailed description of these analytical techniques and their application to dairy peptides has been recently reviewed [4]. Research performed to date has found certain structure–activity relationships for bioactive peptides, that is, peptides with a given activity share specific structure cluster or have sequence requirements.

This chapter deals with the methods applied to test the bioactivity of food-derived peptides. The common structural features of peptides exhibiting a particular activity will also be summarized. Special attention will be focused on the in vitro methods used to evaluate bioactivity and the in vivo animal models employed.

3.2  Evaluation of Peptide Bioactivity

Evaluation of peptide bioactivity is one of the most important challenges in the search for novel bioactive sequences and usually it cannot be accomplished by the use of a single method. To perform an initial screening of numerous sequences or fractions, rapid and simple in vitro methods are required. Once they are liberated, they can act locally, at any point of the gastrointestinal tract, or they have to be absorbed to reach the target organ. In this latter case, bioavailability of the peptides and changes that can occur during digestion, absorption, or distribution have to be evaluated using cell cultures, ex vivo organ preparations, or in vivo animal models. Finally, there is consent over the fact that health claims must be proved in human studies.

3.2.1  Antihypertensive Peptides

Antihypertensive peptides are probably the most extensively studied bioactive peptides from foods and, in fact, an important progress has been made in the area of blood pressure reduction by the use of food peptides. This can be, at least partially, explained because hypertension is a significant problem worldwide and one of the major controllable risk factors associated with cardiovascular diseases [5]. Inhibition of angiotensin-converting enzyme (ACE) is regarded as the main mechanism of action of the antihypertensive activity of food peptides. ACE plays an important role in the renin–angiotensin system, regulating arterial blood pressure, as well as the salt and water balance. ACE hydrolyzes angiotensin I into angiotensin II, a potent vasoconstrictor, whereas it degrades bradykinin, a potent vasodilator [6]. The measurement of the reduction in the formation of angiotensin II in vitro is a common test for evaluating ACE inhibition exerted by different drugs and food peptides. The IC50 value (the inhibitor concentration that leads to 50% inhibition) is used to compare the effectiveness of different ACE inhibitory peptides. Once the IC50 value has been established, it represents an approximation to the possible antihypertensive effect of these compounds [7].

Several methods can measure the ability of food peptides to inhibit ACE in vitro. One of the most commonly used ones was developed by Cushman and Cheung (1971) [8], and later modified by Nakamura et al. [9]. This method employs the compound hyppuryl–histidil–leucine (HHL) as the substrate of ACE, which releases the dipeptide His–Leu and hyppuric acid. The amount of hyppuric acid is quantified spectrophotometrically at 228 nm once it has been extracted with ethyl acetate. However, it is a tedious process that can overestimate ACE activity if nonhydrolyzed HHL is also extracted, although this can be avoided by HHL separation and quantitative determination by high-performance liquid chromatography (HPLC) that also has the problem to be a time-consuming method to evaluate ACE-inhibitory activity [10].

Other spectrophotometric methods have been optimized and validated, such as that based on the release of the dipeptide Gly-Gly (GG) when the enzyme reacts with the substrate furanacryloyl-Phe-Gly-Gly (FAPGG) [11]. This method was later evaluated and it was demonstrated that the level of ACE activity in the assay determines apparent IC50 value obtained. Therefore, for comparative purposes, it is necessary to detail the number of enzyme units used and include in the study a standard ACE inhibitor, such as Captopril [12]. Later, a fluorescence assay which employs o-aminobenzoylglycyl-p-nitrophenylalanylproline as the substrate of ACE was developed [13]. The fluorescence generated by the release of the o-aminobenzoylglycyl group is read on a microplate fluorimeter, resulting in a simple, rapid, and sensitive method that allows a continuous monitoring of ACE activity in just one step.

A biochemical assay based on a continuous-flow enzyme–substrate reaction and the subsequent detection of the reaction products by mass spectrometry has been developed and applied to the screening of complex extracts of peptides with ACE-inhibitory activity. The inherent advantage of this method is that the fractionation of peptides for further activity testing is avoided, although an online HPLC-mass spectrometer is needed [14]. Recently, a new turbulent flow cytometry (TFC)/electrospray ionization mass spectrometry (ESI-MS)-based screening method has been developed. In contrast to the methods previously described, this approach uses the natural ACE substrate angiotensin I, instead of artificial substrates. The ACE assay is carried out in an atypical offline setup by incubation of the samples with ACE and angiotensin I followed by stopping the reaction with acetonitrile containing val5-angiotensin I, which serves as an internal standard. Angiotensin I and the product angiotensin II are extracted from the incubation mixture by TFC applied in backflush mode as online solid-phase extraction and are directly quantified by ESI-MS. The presence of inhibitors is detected by an increase in the angiotensin I signal intensity and a corresponding decrease of angiotensin II signal, as compared to the blank assay. This parallel (two-way) measurement of the inhibitory activity allows the exclusion of false-positive results caused by interfering matrix compounds. No laborious cleanup is required and the incubation mixture can be analyzed directly after stopping the ACE conversion. The whole TFC/ESI-MS analysis takes <5 min making the method also suitable for a rapid screening of a large set of samples [15].

The structure–activity relationship of ACE-inhibitory peptides has been extensively studied and it is accepted that binding to ACE is strongly influenced by the C-terminal sequence of the peptide. ACE-inhibitory peptides seem to share, as a common structural property, the presence of hydrophobic amino acid residues (with aromatic or branched side chains) at each of the three C-terminal positions. Some of the most potent ACE-inhibitory peptides reported have a proline residue at the end of their sequence. In addition, the presence of a residue of proline at the C-terminal and antepenultimate position appears to enhance binding while ACE only binds weakly to peptides that have penultimate proline residues [16,17]. Later on, it has also been confirmed that the presence of another hydrophobic amino acid, such as leucine as C-terminal end helps inhibit ACE [18]. C-terminal lysine or arginine also seems to contribute to the inhibitory activity of the peptides, which suggests a possible interaction between a positive charge of the inhibitor and an anionic-binding site of ACE [19]. For instance, when the C-terminal proline residue of peptide LHLPLP was substituted by arginine (LHLPLR), the resultant peptide was twice more potent than the parent peptide. However, substitution of the C-terminal proline by leucine yielded a similar activity [20]. It is important to note that ACE-inhibitory activity also depends on the conformation of the peptides. It has been shown that the peptide DKIHP containing trans-proline exerts a more potent ACE-inhibitory activity than the conformer with cis-proline. It was suggested that the change of a trans-form into a cis-form of proline could cause significant changes in the peptide structure and in its interaction with the active site of the enzyme [21].

Very often, the attempts to corroborate the antihypertensive effect of peptides with ACE-inhibitory properties reveal a lack of correlation between the in vitro ACE-inhibitory activity and the in vivo action [22]. This is probably because the selection of potentially antihypertensive food peptides is solely based on the in vitro determination of the ACE-inhibitory activity, while important aspects such as the physiological transformations that determine the bioavailability of the peptides or the existence of other mechanisms of action are overlooked [23]. In fact, antihypertensive food peptides with mechanisms of action other than ACE inhibition, such as those possessing antioxidant, vasodilator, and opioid activities, have been reported [2428].

Some peptides derived from food proteins exert direct effects on vascular smooth muscles [25] or modulate the release of endothelium factors that relax or contract vascular smooth muscles [26,2832]. To study the vasodilator activity produced by different peptide sequences, organ baths are used. Isolated rings from conduit arteries or resistance vessels from normotensive or hypertensive rats are mounted in isolated tissue chambers containing a physiologic solution at 37°C and continuously bubbled with a 95% O2–5% CO2 mixture, which gives a pH of 7.4. After an equilibration period, the functionality and the maximum contractility of the rings are tested by adding KCl. The functional integrity of the endothelium can be confirmed by the relaxation response to acetylcholine of segments previously contracted with a vasoconstrictor agent. The absence of relaxation induced by acetylcholine confirms the absence of endothelium. Afterward, the relaxation produced by a single (not >0.1 mM) or several concentrations (0.1 μM–0.1 mM) of the peptide can be evaluated in precontracted segments. The effects of different inhibitors such as a nitric oxide (NO) synthase inhibitor (L-NAME), or a cyclooxygenase inhibitor (indomethacin), on the relaxation induced by the peptides can be studied by their addition 30 min before precontraction of the vessels.

There are very few studies dealing with the effects of food peptides on the vascular function, so that the structure–activity relationship of vasodilator peptides is not as yet well established. In contrast to the ACE-inhibitory activity, it seems that the N-terminal residue is more important than the C-terminal residue to the vascular-relaxing activity [33]. It has been suggested that amino acids, such as arginine or tyrosine, are important at the N-terminal position [28,34]. In addition, small variations in the amino acids at certain positions could lead to different vasorelaxing mechanisms. This is the case of the hypotensive peptides ovokinin (2–7) (RADHPF) and novokinin (RPLKPW). NO and B2 bradykinin receptors are implicated in the mechanism of action of ovokinin [29,31], while the vasorelaxing activity of novokinin, a potent hypotensive peptide acting through the AT2 receptor, is mediated by prostacyclin [35].

In any case, to evaluate the antihypertensive activity of these compounds, experiments on animals and humans are necessary and of particular importance. Several studies have been performed using animal models to determine the antihypertensive effects of food peptides after short- and long-term treatments [22,3642]. Spontaneously hypertensive rats (SHRs), developed from Wistar rats bred at Kyoto University [43], constitute the most widely used experimental model for hypertension, because the basic principles associated with the onset of hypertension in these animals are surprisingly similar to those in humans [44,45]. Wistar–Kyoto rats are the normotensive control of SHRs. The rats’ arterial blood pressure is usually measured by a modification of the tail cuff method, a noninvasive method originally described by Buñag [46]. In most studies, the acute effect caused by the oral administration by gavage of a single dose of the peptide is evaluated and the rats’ arterial blood pressure is measured before this administration, and then at 2 h intervals for 8 h. Arterial blood pressure is again measured 24 h after administration. For these acute administration experiments, rats with stable arterial blood pressure values (and thus older than 20 weeks) should be used. As an example, Figure 3.1 shows the antihypertensive effect of egg-white-derived peptides after a single oral administration to SHRs (Figure 3.1) [39]. The antihypertensive activity can also be evaluated using radiotelemetric monitoring in conscious rats [47,48]. The telemetric transmitters are implanted into the abdominal aorta by a feasible surgical procedure. This method has the advantage that it avoids the animal stress produced when several measurements are performed in a small period of time.

Decrease in systolic blood pressure (SBP) caused in SHRs by the administration of water (○), captopril (50 mg/kg) (□), and the peptides (10 mg/kg): YRGGLEPINF (♦), RDILNQ (▲), and ESIINF (■). The data represent the mean values ± SEM for a minimum of five animals. *

Figure 3.1   Decrease in systolic blood pressure (SBP) caused in SHRs by the administration of water (○), captopril (50 mg/kg) (□), and the peptides (10 mg/kg): YRGGLEPINF (♦), RDILNQ (▲), and ESIINF (■). The data represent the mean values ± SEM for a minimum of five animals. *P < 0.05 versus water; #P < 0.05 versuss captopril; P was estimated by a two-way analysis of variance. (From M. Miguel et al. J Agric Food Chem. 55: 10615–10621, 2007. With permission.)

Hypertension is a chronic pathology which requires chronic treatments; therefore, it is advisable to follow the changes in the arterial blood pressure of SHRs caused by a long-term oral intake of food peptides. In these experiments, the development of hypertension in the rats and the role played by the peptides administered is assessed. In experimental studies of chronic administration to SHRs, arterial blood pressure is measured at the same time of day (usually in the morning), in order to avoid the influence of the circadian cycle. In these studies, the treatment begins at weaning and the products are usually administered in the animals’ drinking water. Continuation of the measurements after withdrawal of the treatment allows the evaluation of the possible reversal of the effects. Food intake, water intake, and body weight gain in the animals can be recorded weekly during all experimental period. At the end of the study, blood and tissue samples of the rats can be obtained after an overnight fasting period, in order to perform biochemical studies to explore the mechanisms of action implicated in the antihypertensive effect of the product.

There are several differences in the bowel structure, function, and microflora between rodents and humans. It is therefore evident that it is necessary to carry out clinical studies in humans to demonstrate the efficiency of the antihypertensive peptides and to guarantee their security. However, only a few human clinical studies have been carried out [4959]. Recent data do not seem to support a positive role of bioactive peptides in blood pressure regulation. However, beneficial effects in hypertensive subjects from specific populations cannot be discarded, and more research is needed to elucidate mechanisms other than the intervention in the renin–angiotensin system that could be involved [60].

The results of the above-mentioned studies suggest the possibility of using hydrolyzates and peptides from food proteins as health-enhancing ingredients in functional foods, nutraceuticals, and pharmaceutical preparations to reduce the risk of hypertension. Their usefulness may be particularly clear in prehypertensive subjects who do not need antihypertensive medication yet, and who control their blood pressure by dietary means. It is also likely that these products can be of use in hypertensive patients who do not respond well to pharmacological treatments. It should be noted that several of these peptides, which have already proved their safety and effectiveness in hypertensive patients, are currently marketed in functional foods [61].

3.2.2  Antioxidant Peptides

Oxidative stress caused by an abnormal production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in cells has been implicated in the etiology of age-associated chronic diseases, such as cardiovascular diseases, cancer, diabetes, neurodegenerative disorders, and aging [62]. Moreover, it is well known that lipid peroxidation occurring in food products causes deteriorations of food quality and shortening of shelf life. In the past years, the importance of antioxidants in the protection of organisms, tissues, and nonliving systems against oxidative stress has become evident. Artificial antioxidants (butylated hydroxyanisole, butylated hydroxytoluene, and n-propyl gallate) exhibit a strong antioxidant activity against several oxidation systems. However, there is growing concern about their safety, particularly their potential carcinogenicity and genotoxicity [63,64]. This, along with consumer preference for natural occurring bioactive components, has prompted researchers to identify and develop novel natural and cost-effective antioxidants. Recent studies have suggested that food proteins hold promise as a potential dietary source of natural antioxidants. Hydrolyzed proteins from many animal and plant sources, such as milk [65,66], soy [67,68], zein [69], rice bran [70], canola [71], egg-white and yolk [24,72], porcine myofibrillar [73], and fish proteins [7479] have been found to possess antioxidant activity. This activity is believed to be attributed to peptide sequences contained in these proteins and released after enzymatic proteolysis.

The ability of peptide fractions to inhibit deleterious changes induced by lipid oxidation appears to be related to their nature and composition. This seems to be dependent on the specificity of the proteinase used to generate the hydrolyzate [80]. There is evidence that the antioxidant effect of individual amino acids increases when they are incorporated in a peptide, indicating that the peptide bond or the structural conformation have an influence of this activity [81]. Thus, the peptide composition can lead to both synergistic and antagonistic effects with regard to the antioxidant activity of free amino acids. Chen et al. (1996) found that peptides containing a Pro-His-His sequence exhibited the greatest antioxidant activity among a group of tested peptides [67]. In addition, high levels of histidine and of some hydrophobic amino acids were related to peptide antioxidant potency [82]. The activity of histidine-containing pep-tides is thought to be connected to their hydrogen-donating ability, lipid peroxy-radical trapping, and/or the metal-ion chelating ability of the imidazole group [83]. Other amino acids such as tryptophane and tyrosine have also been reported to contribute to the antioxidant activity, because of the capacity of the indolic and phenolic groups, respectively, to serve as hydrogen donors [24,66]. The hydrophobicity of the peptide also appears to be an important factor for its antioxidant activity due to increased accessibility to hydrophobic targets (e.g., lipophilic fatty acids) [84].

Generally, the ideal method for determination of antioxidant properties of peptides should assess their effect under reaction conditions that mimic those occurring when oxidative stress is induced in vivo by RNS and ROS [85]. As it has been observed for other antioxidants, the activity of peptides depends on the assay considered. The antioxidant properties of peptides have been attributed to the cooperative effect of a number of properties, including their ability to scavenge free radicals, to act as metal-ion chela-tors, oxygen quenchers, or hydrogen donors, and to the possibility of preventing the penetration of lipid oxidation initiators by forming a membrane around oil droplets. According to these properties, diverse methods have been proposed to measure the antioxidant activity of peptides derived from food proteins.

In the last few years, the Oxygen Radical Absorbance Capacity assay has been widely used to determine the antioxidant capacity of peptides derived from milk-whey proteins [66,81,86], egg [24], soy [87], seafood muscle [88], and fish proteins [89]. In the basic assay, the peroxyl radicals generated react with a fluorescent oxidizable protein substrate to form a nonfluorescent product. Probe reaction with peroxyl radicals is followed by a loss of the intensity of fluorescence with time. This assay measures the antioxidant inhibition of peroxyl-radical-induced oxidations and reflects a classical radical chain breaking antioxidant activity by H-atom transfer [90]. The low cost of the material and the possibility of using an automated fluorescence reader are the two main advantages of this assay. Moreover, it is particularly useful for samples which contain multiple ingredients with antioxidant activity.

The Trolox Equivalent Antioxidant Capacity (TEAC) assay has become one of the most widely used methods in testing the antioxidant capacity of food peptides from different sources. It has been applied to vegetal proteins, such as soy [91,92], zein [93], and rice bran proteins [94], among others. Hydrolyzates from animal proteins, such as milk and fish proteins, have also been analyzed for antioxidant activity with this method [66,9597]. This assay uses 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), a peroxidase substrate, which when oxidized, generates a metastable radical cation (ABTS•+). This radical is intensely colored and can be monitored spectrophotometrically in the range of 600–750 nm. The antioxidant capacity is measured as the capacity of test compounds to decrease the color by reacting directly with ABTS•+ radical, and expressed relative to that of 6-hydroxy-2,5,7,8tetramethylchroman-2-carboxylic acid (Trolox) [98]. This assay is often used to rank antioxidants to study structure–activity relationships [99]. Because the ABTS•+ radical can be solubilized in both aqueous and organic media and it is not affected by the ionic strength, the antioxidant capacity of hydrophilic and lipophilic compounds can be measured [100]. However, this method has two important limitations. On the one hand, the TEAC value actually characterizes the capability of the tested sample to react with ABTS•+ rather than to inhibit the oxidative process. On the other, the ABTS radical used in TEAC assays is not similar to the radicals found in biological systems [101].

In the 1,1-diphenyl-2-picrylhydrazyl (DPPH) Radical Scavenging Capacity Assay, the purple chromogen radical DPPH is reduced by antioxidant/reducing compounds to the corresponding pale yellow hydrazine. The reducing ability of the antioxidants can be evaluated by monitoring the absorbance decrease at 515–528 nm, until the absorbance remains stable or by electron spin resonance. This assay is technically simple and rapid and it only requires a UV–vis spectrophotometer that might explain its widespread use in antioxidant screening. An important limitation of this method is the interpretation of the role of hydrophilic antioxidants, because DPPH can only be dissolved in organic media [100]. However, many authors have used this assay for measuring the antioxidant activity of peptides from food proteins [87,93,102108].

The ferric reducing antioxidant power assay is based on the reduction of yellow ferric tripyridyltriazine complex (Fe(III)-TPTZ) to blue ferrous complex (Fe(II)-TPTZ) by the action of electron-donating antioxidants [109]. The resulting blue color, measured spectrophotometrically at 593 nm, is taken as linearly related to the total reducing capacity of electron-donating antioxidants. This assay is rapid, simple, robust, inexpensive, and it does not require specialized equipment. Therefore, it has become one of the preferred methods to determine the antioxidant activity of peptides from several food protein sources [88,96,110].

In general, in vitro low-density lipoproteins (LDL) oxidation has been effectively used in several studies to characterize the antioxidant capacity of a number of different phytochemicals [111114] and food peptides [115117]. This method artificially induces the autoxidation of linoleic acid or of LDL particles, and the peroxidation of the lipid components is determined through the formation of conjugated dienes, followed by a spectrophotometrical analysis at 234 nm [118]. Basically, there are three mechanisms involved: free radical scavenging activity, binding to critical sites on LDL, and metal chelation [112].

Currently, different methods are being used to analyze the inhibitory properties of food peptides on ROS generation and on lipid peroxidation in different cell lines as the basis of their ability to reduce oxidative stress. For instance, estrogen-independent breast cancer cells were employed by Hernández-Ledesma et al. [92] to evaluate the antioxidative effect of the peptide lunasin in macrophages RAW 264.7.

Many food-derived peptides are effective as in vitro antioxidants but, due to the variable reports on their in vivo efficacy and the pro-oxidant nature of some antioxidants, it is necessary to perform studies in experimental animal models fed with these components to demonstrate the reduction of in vivo oxidative stress by the use of different biomarkers. It is known that compounds that upregulate the production of endogenous antioxidants, such as glutathione and antioxidant enzymes, provide novel approaches for the restoration of redox homeostasis. The values and enzymatic activities of these compounds, as well as the total antioxidant capacity, can be evaluated in the plasma and tissues of animals by enzymatic–colorimetric methods [119121].

3.2.3  Antimicrobial Peptides

In the past 20 years, there has been an increasing interest in antimicrobial peptides present in men and animals, because they are considered to possess the functions in host defense, inflammation, and tissue generation [122,123]. In addition to these, it has also been demonstrated that several food proteins and peptides exert antimicrobial activities that can also provide protection against infection [124,125].

Numerous studies have been performed to understand the relationship between the structure and the activity of antibacterial peptides, especially of antibiotics peptides that act as components of the host defenses of animals or plants. An amphiphilic, mostly α-helical conformation, and an excess of positive charges are recognized as major structural motifs determining the membrane-disturbing activity of these peptides. These cationic and hydrophobic peptides are demonstrated to act by direct interaction with specific anionic membrane components, orientated toward the exterior of the cell, promoting pore formation and bacterial membrane disruption. Other peptides have membrane-permeabilizing properties and cell-penetrating activity. Some of these structural characteristics are also found in food-derived peptides.

The antibacterial activity of some dietary peptides can be tested by an agar diffusion assay where the peptide diffuses from a paper disc or small cylinder into an agar medium that contains test organisms. Inhibition is observed as the failure of the organism to grow in the region of the peptide. This method has been used, for instance, as a preliminary test to characterize the antibacterial activity of peptides obtained after the fermentation of casein with Lactobacillus acidophilus [126] and of peptides from human milk [127]. More frequently, the antimicrobial activity is determined in a liquid medium, commonly by using a microtiter plate assay, and measuring bacterial growth by optical density or bacterial count. Results are compared by establishing the minimum inhibitory concentration of a peptide/hydrolyzate for a given microorganism, that is, the lowest peptide/protein concentration that shows no growth at the end of the experiment. To compare the activity of different peptides or hydrolyzates, the IC50 value, defined as the concentration required to obtain 50% inhibition of growth at the exponential phase of growth, is also employed [128]. This assay has been widely used and recent applications include the assay of the antimicrobial activity of human milk against Escherichia coli and Listeria monocytogenes [129], synthetic porcine lactoferricin against Staphylococcus aureus and Candida albicans [130], αs2-casein-derived peptides [131], and lactoferrampin [132].

The use of a bioluminescence assay to follow bacterial growth and metabolism has been also applied to investigate the effect of hydrolyzates of α-lactalbumin and β-lactoglobulin against E. coli JM103 [133]. Bacterial enumeration through fluorescent in situ hybridization has also been used to study the effect of α-lactalbumin and glycomacropeptide on mixed populations of human gut bacteria [134]. In the latter example, in addition to a batch culture, a two-stage continuous culture model was used, with the advantage of allowing spatial and temporal heterogeneity and the assay of more complex environmental conditions.

Electron microscopic examination of bacterial preparations has also been used for lactoferricin, other lactoferrin-derived peptides [135], and αs2-casein-derived peptides [129]. As an example, Figure 3.2 shows the transmission electron microphotographs corresponding to intact cells of E. coli ATCC 25922 cells and cells incubated with bovine αs2-casein f(183–207) or lactoferricin. This technique allows the detection of damage in bacterial membranes and changes in the cytoplasm. With the aim of studying the mechanism of action of these antibacterial peptides, other techniques, such as circular dichroism analysis with micelles or liposomes, peptide binding to microbial cell components, and nuclear magnetic resonance spectroscopy, among others, have been successfully employed, but they fall out of the scope of this chapter.

There exist only a few studies on the in vivo activity of antimicrobial dietary peptides performed using animal models or in clinical trials in humans. Studies using animal models have reported a protective effect of orally administered lactoferricin against infections by methicillin-resistant S. aureus [136] or by the parasite Toxoplasma gondii [137]. Most of these studies were performed to demonstrate the antibacterial effects of the entire protein lactoferrin after oral administration. However, as orally administered lactoferrin is partially degraded to fragments that contain the lactoferricin sequence [138,139], some of these effects can probably be attributed either to lactoferrin fragments or to the combined action of lactoferrin and its derived peptides.

TEM micrographs of

Figure 3.2   TEM micrographs of E. coli ATCC 25922. (a, b) Untreated cells. The arrow in (b) indicates the periplasmic space. (c, d) Cells treated with bovine αs2-casein f(183–207) at a concentration of 31 μM during 2 h at 37°C. Arrows in (d) indicate the loss of continuity of the membrane and the swollen area between inner and outer membranes. (e, f) Cells treated with lactoferricin-B at a concentration of 31 μM during 2 h at 37°C. The arrow in (e) indicates a blister in the outer membrane. (From I. López-Expósito, L. Amigo, and I. Recio. BBA Biomembranes 1778: 2444, 2008. With permission.)

In humans, a study with low birth-weight infants fed with a lactoferrin-enriched infant formula concluded that lactoferrin contributes to the formation of a bifidobacteria-rich flora [140]. Lactoferrin has also demonstrated to be effective in the eradication of Helicobacter pylori when used as a supplement to an antibiotic treatment [141]. Other in vivo studies on lactoferrin to investigate its antiviral and immunomodulatory effects, as well as other host-protective activities, such as cancer prevention, and clinical applications have been reviewed [142,143].

There exist some studies on the in vivo activity of isracidin, corresponding to αs1-casein f(1–23). In mice, it exerts a protective effect against L. monocytogenes, Streptococcus pyogenes, and S. aureus. Protection of rabbits, guinea pigs, and sheep against S. aureus has also been achieved. In cows with mastitis, isracidin obtained a success rate of over 80% in the treatment of chronic streptococcal infection. Furthermore, it has been demonstrated that isracidin possesses immunomodulant properties, with a significant effect in the production of IgG, IgM, and antibody-forming cells and an enhancing effect on cell-mediated immunity when injected to mice [144]. Another interesting finding was made with a tryptic casein hydrolyzate for the treatment and prophylaxis of newborn calf colibacillosis [145]. Recently, a product obtained from bovine colostrum rich in immunoglobulins, growth factors, antibacterial pep-tides, and nutrients was demonstrated to reduce the number of evacuations of stools per day in patients with HIV-associated diarrhea [146].

3.2.4  Opioid Peptides

Accumulated evidence shows that peptides from food proteins may act as opioid receptor ligands, and thus, they may be regarded as exogenous supplements to the endogenous opioidergic systems of the human organism. They have been referred to as exorphins, to distinguish them from opioid peptides of endogenous origin, called endorphins. Opioid receptors (μ-, δ-, and κ-type) are located in the nervous, endocrine, and immune systems, as well as in the intestinal tract of the mammalian organism and they can interact with their endogenous ligands, as well as with the dietary opioid and opioid antagonists [147]. Orally administered food-protein-derived peptides have demonstrated to influence postprandial metabolism by stimulating the secretion of insulin and somatostatin [148,149], to modulate intestinal transport of amino acids [150], to prolong gastrointestinal transit time, and to exert antidiarrheal action [151]. Recently, it has been proposed that β-casomorphin-7 may contribute to mucin production via a direct effect on the intestinal goblet cells and an activation of μ-opioid receptors [152]. They may also play a role in the reproductive function of the female organism, supporting processes of pregnancy, delivery, and lactation period, while they may exert a cardioprotective function in pregnant or lactating mammals [153].

The common structural characteristic of opioid peptides is the presence of a tyrosine residue at the amino terminal end (except milk-derived α-casomorphins that have an additional arginine residue) and the presence of another aromatic residue in the third or fourth position. The negative potential, localized in the vicinity of the phenolic hydroxyl group of tyrosine, is essential for opioid activity and the presence of a proline residue helps maintain the proper orientation of the tyrosine residue and the other aromatic amino acids [154,155]. The occurrence of aliphatic amino acids in the third position also contributes to the opioid activity in the case of gluten exorphins and neocasomorphin (YPVEPF).

Food-derived peptides can be screened for opioid activity by measuring the adenylate cyclase activity in homogenates of neuroblastoma X-glioma cells and using naloxone as opioid antagonist to reverse the effect [156]. The two bioassays employed more often to test materials with opioid activity are the guinea-pig ileum longitudinal muscle myenteric plexus preparation and the mouse vas deferens preparation. Opioid receptors located on intestinal smooth muscle cells are the targets for exogenous μ- and κ-opioid receptors agonists to inhibit the propulsive peristaltic activity and to increase the smooth muscle tone [157]. The mouse vas deferens are classical preparations for studying the pharmacology of δ-opioid receptors [158]. The activity in these two organ bath preparations can be antagonized with opioid antagonists, such as naloxone. Further, specific radioligand competition assays for opioid μ-, δ-, and κ-sites have also been used for assessment of opioid peptides [159].

Several animal models have been used after oral or intragastrointestinal administration of food-protein-derived opioid peptides, which allowed the demonstration of a number of activities for β-casomorphins, milk casein preparations, gluten exorphins, and gluten or gluten hydrolyzates. In dogs, stimulation of insulin release, reduced gastrointestinal motility, and release of somatostatin are observed after intragastric administration of casein [148,160,161]. In rats, satiety was demonstrated to be influenced by casein or casein hydrolyzate [162]. Prolongation of gastric emptying rate and gastrointestinal transit time are also observed after intragastric administration of casein [151]. Several studies have also been performed by using calves and cows. For instance, an antidiarrheic effect is found in calves upon oral administration of β-casomorphin(1–4) amide [163]. The behavioral and antinociceptive effects of these peptides are usually tested in mice. The tail pinch method has been employed in the case of a peptide derived from Rubisco [164]. Effects on nociception, locomotor activity, motor coordination, rectal temperature, and duration of pentobarbital anesthesia have been evaluated in mice after intraperitoneal administration of α-lactorphin (YGLF, an opioid tetrapeptide derived from α-lactalbumin). This peptide, in contrast to morphine, elicits no behavioral effect in mice [165]. Interestingly, this α-lactalbumin-derived peptide has the ability to lower blood pressure in hypertensive and normotensive rats after subcutaneous administration [47]. Another αs1-casein-derived opioid peptide, RYLGY, has recently shown antihypertensive activity in SHRs after acute and chronic administration [27,166].

In adult humans, oral administration of β-casomorphin(1–4) amide delays the gastrointestinal transit time [167]. A gluten hydrolyzate also causes a prolongation of gastrointestinal transit time in healthy volunteers, an effect that is blocked by naloxone [168].

3.2.5  Mineral-Binding Peptides

The first reference to bioactive peptides in the scientific literature was made by Mellander in 1950, who suggested that casein-derived phosphorylated peptides enhanced vitamin D-independent bone calcification in rachitic infants [169]. Later, it was demonstrated that these peptides, also named phosphopeptides, by virtue of their high content of negative charges, efficiently bound divalent cations, specially calcium, but also Fe, Mg, Mn, Cu, and Se, forming soluble complexes. It has also been suggested that the mineral-binding activity could be dependent on the histidine content and peptide size [170,171]. These peptides with mineral-binding activity could then function as carriers of various minerals and thus, either enhance or inhibit their bioavailability.

Mineral-binding peptides are considered physiologically beneficial in the prevention of dental caries, mainly because of their role in recalcification of the dental enamel. The use of these peptides in preventing osteoporosis, hypertension, and anemia has also been proposed [172]. Another interesting property associated with phosphopeptides is their potential to enhance mucosal immunity [173]. It is important to note that the high content of negative charges makes these peptides resistant to further hydrolysis [174], and they have been detected in the gastrointestinal tract of animals and humans after oral ingestion [175177].

Isolation and characterization of peptides with mineral-binding activity requires selective solubilization and precipitation methods [178184]. Differences in mineral affinity, competition for binding sites, and changes in the pH and ionic strength of the solvent are used to influence mineral binding and release. Mineral-binding peptides can be also isolated using ultrafiltration and hydroxyapatite affinity (HA) chromatography [185187], or measuring the calcium content of the supernatant after the formation of a Ca–peptide complex using CaCl2 and sodium phosphate buffer [188].

The beneficial properties of phosphopeptides can be estimated in vitro by selective precipitation, using a model system based on HA. In this method, the peptides are incubated with a suspension of HA in Tris buffer at pH 7.0, as a replacement for dental enamel and sodium acetate buffer at pH 4.2, is added to simulate the organic acids found in the mouth. After centrifugation, the supernatant is used to measure the levels of calcium and phosphorus dissolved from the HA by the action of the sodium acetate buffer, which represents 100% demineralization. The effectiveness of peptides samples to reduce the demineralization of HA is deduced by comparing calcium and phosphorous concentrations in the protein/peptide supernatant with the values of the controls [189191].

The measurement of the mineral content is complex and depends on several factors. Among these, the equilibrium status, redox form, solubility, and binding affinity are regarded as some of the most important ones. Sensitivity of the method is also important [174]. For instance, analysis of total calcium, iron, zinc, magnesium, and some trace elements can be performed by atomic absorption spectroscopy [192], colorimetric methods measure the ferrous form of iron [193,194], and chromatography in the presence of chelating agents can be applied as a selective technique [193,195,196]. It is also possible to use radioactive isotopes to follow the binding mechanism [197199].

Improved in vitro methods utilize human colon carcinoma cell lines (Caco-2) [200] to mimic and estimate the uptake and/or transport of mineral elements [201]. Other cell lines can also be employed to assess the potential of peptides to enhance the dietary mineral bioavailability and to modulate the bone formation [202], such as bone-marrow-derived osteoblast precursor cells, to measure the ability of food-derived peptides to stimulate the proliferation of osteoblasts to form osteoclasts [203]. However, these in vitro methods only estimate the fraction of elements available for absorption [204], and thus, mineral bioavailability should be evaluated in vivo [205], assessing intestinal calcium absorption in rats [206], or enhanced bone calcification [207,208].

3.2.6  Antithrombotic Peptides

It is generally accepted that platelet adhesion and aggregation play an important role in the pathogenesis of thrombosis, particularly arteriothrombosis [209]. Antithrombotic agents are widely used in medicine for the treatment of several cardiovascular events and related diseases, such as coronary angioplasts, coronary thromboembolisms, myocardiac heart attack, pulmonary embolism, and so on [210]. The formation of thrombin consists of the binding of fibrinogen to its platelet receptors after activation by physiological agonists such as adenosine diphosphate (ADP), thrombin, and collagen [211]. One of the sites at which fibrinogen binds to platelet receptors corresponds to the C-terminal sequence of the γ-chain, the 400–411 fragment (HHLGGAKQAGDV) [212]. In vitro and in vivo experiments have demonstrated that food peptides analog to this sequence, such as casein macropeptide that derives from κ-casein, are capable of inhibiting the binding of the human fibrinogen γ-chain to fibrinogen receptors on the platelets surface, what would otherwise lead to platelet aggregation [213218]. These peptides have been detected in plasma of new born children after ingestion of breast milk or infant formula, although their in vivo significance remains unclear [219].

The antithrombotic activity can be evaluated in vitro, by assessing the inhibition of fibrinogen binding to ADP-activated platelets. For this purpose, platelet-rich plasma is incubated with the peptides and, after addition of ADP, the increase in light transmission is monitored using an aggregometer [175,213,220]. The antithrombotic activity can be also studied in vivo using a guinea-pig model of arteriolar thrombosis, which is triggered by a laser-induced minimal injury [216,221223].

3.2.7  Hypocholesterolemic Peptides

Hyperlipidemia, especially hypercholesterolemia, is one of the most important risk factors contributing to the development of cardiovascular diseases [224227]. Plasma cholesterol levels are influenced by the diet and by cholesterol biosynthesis, uptake, and secretion [228231]. Considerable evidence indicates that cholesterol lowering stabilizes atheroma plaques reducing cardiovascular events [232235]. In the last few years, numerous drugs and natural extracts have been explored for their potential in the prevention and treatment of hypercholesterolemia. In this context, food-derived peptides might also lower serum cholesterol levels [229,230,236239], by increasing cholesterol catabolism, reducing intestinal absorption of dietary cholesterol or inhibiting cholesterol uptake from the plasma into the liver, preventing the deposition of cholesterol into plaques on the arterial wall [240].

Hydrophobicity seems to be responsible for the hypocholesterolemic potential of peptides, especially for their bile acid-binding ability and it has also been suggested that the hypocholesterolemic activity is strongly influenced by the presence of a leucine residue at the N-terminal side [241]. Further work is required to identify hypocholesterolemic peptides, and to clarify the influence of peptide structure on the hypocholesterolemic activity.

Cholesterol is water insoluble and requires a micellar solubilization step prior to intestinal absorption [242]. In vitro assays relate the hypocholesterolemic action of proteins and peptides with their ability to decrease the micellar solubility of cholesterol and with their taurocholate-binding capacity. To study micellar solubility in vitro, the sample is incubated with either artificially prepared or natural micellar solutions containing sodium taurocholate, cholesterol, oleic acid, and sodium phosphate at pH 7.4 and, after ultracentrifugation, the cholesterol content is measured [236,239]. On the other hand, the taurocholate-binding capacity determines the ability of the peptide to bind bile acids in vitro [243,244]. Peptides are incubated with a Tris–HCl buffer containing taurocholate, at 37°C for 30 min, and the content of taurocholate is measured enzymatically after dialysis of the mixture [245,246]. Other in vitro methods apply monolayers of Caco-2 cells as a model system to examine in vitro cholesterol absorption [231,236,247].

In vivo hypocholesterolemic activity can be studied using different animal models, such as rabbits [248], normal rats [249], diabetic rats [250], diabetic and nondiabetic hamsters, [251], guinea pigs [252], and monkeys [253]. For the induction of hypercholesterolemia, they are fed with a cholesterol-enriched diet, prepared by adding cholesterol and cholic acid to the standard diet, during several weeks [254]. Cholic acid is included because it increases micelle formation and facilitates intestinal absorption of cholesterol. At the end of the experimental study, the serum lipid profile (cholesterol and triglyceride levels) can be determined using commercial kits. It is also useful to measure liver function enzymes, such as the rate-limiting enzyme responsible for bile acid biosynthesis, cholesterol 7α-hydroxylase, and the rate-limiting enzyme responsible for the cholesterol synthesis system, 3-hydroxy-3-methylglutaryl coenzyme A reductase [255,256], or the incorporation of [3H]-cholesterol into the serum, liver, and intestine of the animals [257].

3.2.8  Antiproliferative and Cytotoxic Peptides

Cancer has become one of the most common causes of death in industrialized countries and it has been defined as the medical challenge of our times. An impressive body of evidence supports the notion that prevention can be a major component of cancer control. Epidemiological cell culture and animal studies have demonstrated that a large number of natural compounds present in the diet could lower cancer risk and even sensitizes tumor cells in anticancer therapies [258].

Carcinogenesis is a multistage process with an accumulation of genetic alterations, so that the sequence of events has many phases for intervention with the aim of preventing, slowing down, or reversing the process. Based on various cytochemical studies, there is an increasing evidence for the possible involvement of food-protein-derived peptides as specific signals that can inhibit the viability of cancer cells [259]. These studies are based on the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described by Holst and Oredsson [260]. In this assay, MTT is added to the growth medium of the cells, taken up by living cells via endocytosis and reduced to blue formazan crystals inside the cell via complex I in the mitochondrial respiratory chain. The amount of formazan generated is assumed to be directly proportional to the cell number when using homogeneous cell populations [260]. As an example, this method has been used to evaluate the cell proliferation inhibitory properties of peptides from different food protein sources, such as the lactoferricin [261], lunasin from soy protein [262], and lunatusin from lima beans protein [263].

Induction of apoptosis is considered to be one of the important targets in a cancer preventive approach. A regulated form of cell death is a complex process that involves the active participation of the affected cells in a self-destruction cascade and it is defined by a set of characteristic morphological hallmarks, including membrane blebbing, shrinkage of cell and nuclear volume, chromatin condensation, and nuclear DNA fragmentation due to endonuclease activation. Several studies have demonstrated the role of food peptides as apoptosis-inducing agents in different human cancer cell lines [264,265]. As an example, Hsieh et al. [262] have studied recently the effect of the peptide lunasin, alone or in combination with aspirin on the programmed death of estrogen-independent MDA-MB-231 breast cancer cells (Figure 3.3).

New technologies, such as DNA microarrays and serial analyses of gene expression, have created an exciting new frontier for the nutrition and healthcare community. These technologies allow the simultaneous analysis of the expression of thousands of genes and the comparison between normal and abnormal tissues. Therefore, they are being widely used to identify and characterize the response to preventive and therapeutic interventions. Moreover, these techniques are useful for a better understanding of the mechanisms involved in the cancer-preventive actions of food compounds [262,266]. Other techniques are being developed and refined to assist in the identification of the proteome, defined as all proteins present in the cell in a particular cellular time [267]. This type of investigation is very important because of the fact that gene expression does not always correlate with protein expression and the influence of food components may be either translational or posttranslational, rather than at the transcriptional level [268]. Thus, proteomic-based studies, although technically challenging, complement genomic studies, being essential in any comprehensive research strategy aimed at examining the molecular processes and factors involved in modulating cancer risk.

Lunasin promotes aspirin-induced apoptosis. (a) Flow cytometry-based Annexin V labeling of apoptotic cells. Cells were treated for 48 h with vehicle, 1 μM lunasin, 10 μM lunasin, 2 mM aspirin, 1 μM lunasin + 2 mM aspirin, and 10 μM lunasin + 2 mM aspirin. (b) Early and late stages of apoptosis were identified by Annexin V + /7-AAD− and Annexin V + /7-AAD+, respectively in breast cancer cells treated with aspirin, lunasin, and their combination at different concentrations. Three independent experiments were performed (*

Figure 3.3   Lunasin promotes aspirin-induced apoptosis. (a) Flow cytometry-based Annexin V labeling of apoptotic cells. Cells were treated for 48 h with vehicle, 1 μM lunasin, 10 μM lunasin, 2 mM aspirin, 1 μM lunasin + 2 mM aspirin, and 10 μM lunasin + 2 mM aspirin. (b) Early and late stages of apoptosis were identified by Annexin V + /7-AAD− and Annexin V + /7-AAD+, respectively in breast cancer cells treated with aspirin, lunasin, and their combination at different concentrations. Three independent experiments were performed (*P < 0.0001 versus vehicle-treated cells; # P < 0.05, § P < 0.0001 versus aspirin-treated cells). (From C.-C. Hsieh, B. Hernández-Ledesma, and B.O. de Lumen. Food Chem 125: 630, 2011. With permission.)

The animal experiments represent the next step to demonstrate the cancer-preventive activity of food peptides. Transgenic and knockout models present evidence that genes markedly influence the response to dietary components, also providing valuable clues about their site(s) of action [269271]. Other animal models commonly used to evaluate the preventive role of food peptides are those based on chemical and radiation-induced carcinogenesis. As an example, the soybean Bowman–Birk protease inhibitor (BBI) and the BBI concentrate have shown to exert a suppressive effect on 7,12-dimethylbenza(a)anthraceneinduced oral cancer [272], 3-methylcholanthrene-induced lung cancer [273], methylbenzylnitrosamineinduced esophageal cancer [274], radiation-induced lymphosarcomas [275], and ovarian sarcomas [276]. BBI and other peptides, such as lunasin, have also demonstrated anticarcinogenic properties against different types of cancer using xenograft mouse models [277279]. These models are based on the injection of human tumor cells to evaluate the progress of these cells under the effects of chemopreventive pep-tides. Finally, some peptides, such as BBI, are currently being used in large-scale human trials, which represent the last step in demonstrating their cancer preventive role [280].

3.3  Future Prospects

The known bioactive peptides present in food, or produced upon food processing or ingestion, can improve the health status through reductions in blood pressure, enhancement of human defenses (antimicrobial, antioxidant, and cytomodulatory peptides), or modulation of the absorption of nutrients (mineral and cholesterol absorption). Future research in the field of bioactive peptides will focus on the identification of novel bioactive sequences, on the possible mechanisms of action and on new health benefits. In addition to the search for novel peptide sequences with traditional functionalities, other bioactivities will be explored. Of special interest are bioactivities related with the gastrointestinal tract. For instance, it has been found that peptides can affect gastric hormones that control gastric and intestinal motility and secretions or stimulate the release of satiety hormones, such as cholecystokinin [281,282]. Some of these activities are exerted by modulating and influencing gene expression, being the role of dietary peptides in nutrigenomics an undoubtedly growing field of research [283].

The techniques used to study such benefits have improved over the recent years and unique tools have now become available that facilitate the undertaking of challenges that were impossible only one decade ago. The use of advanced peptidomic analytical tools, mainly tandem mass spectrometry analysis, has led to the identification of minor peptides in complex mixtures and biological fluids. Theoretical predictions and simulations are also considered emerging tools in peptide science. These include structure–activity studies based on in silico analysis using chemometric methods and the use of computational chemistry for the creation of sequence databases of bioactive peptides.

New genomic, proteomic, and metabolomic techniques are now enabling the finding of novel associations between diet and chronic diseases through examination of the functional interactions of food components with the genome at molecular, cellular, and systemic levels. Advances in this area will allow the identification of new biomarkers of the physiological effects of peptides that can be employed to evaluate the peptide bioactivity. The mechanisms underlying many of the biological properties of food-derived peptides are, and will be, the subject of increasing interest. Evidence for the beneficial effects of these peptides and demonstration of their mechanisms of action should be conclusive for the approval of a health claim by the authorities. Although some bioactive sequences are already in the market, it is expected that these peptides will be optimally exploited for human nutrition and health when knowledge in these different areas increases.


This work was financially supported by projects Consolider-Ingenio 2010 CSD2007-0063, AGL2007–65035, AGL2008-01713, and AGL2008-01740 from the Spanish Ministry of Education and Science (MEC) and P2009/AGR-1469 from the Autonomous Community of Madrid. Marta Miguel is a recipient of Ramón y Cajal contract from MICINN, and Blanca Hernández-Ledesma is a recipient of Marie-Curie Outgoing International Fellowship from the European Commission and Spanish National Research Council.


E. Haque , R. Chand , and S. Kapila . Biofunctional properties of bioactive peptides of milk origin. Food Rev Int 25: 28–43, 2009.
H. Korhonen . Milk-derived bioactive peptides: From science to applications. J Funct Foods 1: 177–187, 2009.
A.R. Madureira , T. Tavares , A.M.P. Gomes , M.E. Pintado , and F.X. Malcata . Physiological properties of bioactive peptides obtained from whey proteins. J Dairy Sci 93: 437–455, 2010.
I. Recio and R. López-Fandiño . In L.M.L. Nollet and F. Toldrá (eds), Peptides. Handbook of Dairy Foods Analysis. CRC Press, Taylor & Francis Group, Boca Raton, FL, 2009, pp. 33–77.
F. Hong , L. Ming , S. Yi , L. Zhanxia , W. Yongquan , and L. Chi . The antihypertensive effect of peptides: A novel alternative to drugs? Peptides 29: 1062–1071, 2008.
T. Takano . Milk derived peptides and hypertension reduction. Int Dairy J 8: 375–381, 1998.
G.H. Li , H. Liu , Y.H. Shi , and G.W. Le . Direct spectrophotometric measurement of angiotensin I-converting enzyme inhibitory activity for screening bioactive peptides. J Pharm Biomed Anal 37: 219–224, 2005.
D.W. Cushman and H.-S. Cheung . Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20: 637–1648, 1971.
Y. Nakamura , N. Yamamoto , K. Sakai , T. Takano , A. Okubo , and S. Yamazaki . Purification and characterization of angiotensin-converting enzyme inhibitors from sour milk. J Dairy Sci 78: 777–783, 1995.
J. Wu , R.E. Aluko , and A.D. Muir . Improved method for direct high-performance liquid chromatographic assay of angiotensin-converting enzyme-catalyzed reactions. J Chromatogr A 950: 125–130, 2002.
V. Vermeirssen , J.V. Camp , and W. Verstraete . Optimisation and validation of an angiotensin-convertingenzyme inhibition assay for the screening of bioactive peptides. J Biochem Biophys Methods 51: 75–87, 2002.
B.A. Murray , D.J. Walsh , and R.J. FitzGerald . Modification of the furanacryloyl-L-phenylalanylglycylglycine assay for determination of angiotensin-I-converting enzyme inhibitory activity. J Biochem Biophys Methods 59: 127–137, 2004.
M.A. Sentandreu and F. Toldrá . A rapid, simple and sensitive fluorescence method for the assay of angiotensin I-converting enzyme. Food Chem 9: 546–554, 2006.
A.R. de Boer , T. Letzel , D.A. van Elswijk , H. Lingeman , W.M.A. Niessen , and H. Irth . On-line coupling of high-performance liquid chromatography to a continuous-flow enzyme assay based on electrospray ionization mass spectrometry. Anal Chem 76: 3155–3161, 2004.
M. Siemerink , N.H. Schebb , A. Liesener , A.M. Perchuc , R. Schöni , M. Wilmer , H. Hayen , U. Karst , and M. Vogel . Development of a fast liquid chromatography/mass spectrometry screening method for angiotensin-converting enzyme (ACE) inhibitors in complex natural mixtures like snake venom. Rapid Commun Mass Spectrom 24: 687–697, 2010.
H.S. Cheung , F.L. Wang , M.A. Ondetti , E.F. Sabo , and D.W. Cushman . Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. J Biol Chem 255: 401–407, 1980.
M.S. Rohrbach , E.B. Williams , Jr., and R.A. Rolstad . Purification and substrate specificity of bovine angiotensin converting enzyme. J Biol Chem 256: 225–230, 1981.
J. Gómez-Ruiz , M. Ramos , and I. Recio . Angiotensin converting enzyme-inhibitory activity of peptides isolated from Manchego cheese. Stability under simulated gastrointestinal digestion. Int Dairy J 14: 1075–1080, 2004.
M.A. Ondetti and D.W. Cushman . Design of specific inhibitors of angiotensin-converting enzyme—New class of orally active antihypertensive agents. Science 196: 441–444, 1977.
A. Quirós , M.M. Contreras , M. Ramos , L. Amigo , and I. Recio . Stability to gastrointestinal enzymes and structure–activity relationship of β-casein–peptides with antihypertensive properties. Peptides 30: 1848–1853, 2009.
J.A. Gómez-Ruiz , I. Recio , and J. Belloque . ACE-inhibitory activity and structural properties of peptide Asp-Lys-Ile-Pro-[beta-CN f(47–51)]. Study of the peptide forms synthesized by different methods. J Agric Food Chem 52: 6315–6319, 2004.
R.J. FitzGerald , B.A. Murray , and G.J. Walsh . Hypotensive peptides from milk proteins. J Nutr 134: 980S–988S, 2004.
V. Vermeirssen , J.V. Camp , and W. Verstraete . Bioavailability of angiotensin I-converting enzyme inhibitory peptides. Br J Nutr 92: 357–366, 2004.
A. Dávalos , M. Miguel , B. Bartolomé , and R. López-Fandiño . Antioxidant activity of peptides derived from egg white proteins by enzymatic hydrolysis. J Food Prot 67: 1939–1944, 2004.
K. Kuono , S. Hirano , H. Kuboki , M. Kasai , and K. Hatae . Effects of dried bonito (Katsuobushi) and captopril, an angiotensin I-converting enzyme inhibitor, on rat isolated: A possible mechanism of antihypertensive action. Biosci Biotech Biochem 69: 911–915, 2005.
M. Miguel , M.A. Manso , M.J. Alonso , R. López-Fandiño , M.A. Aleixandre , and M. Salaices . Vascular effects, angiotensin I-converting enzyme (ACE)-inhibitory activity, and antihypertensive properties of peptides derived from egg white. J Agric Food Chem 55: 10615–10621, 2007.
M.M. Contreras , R. Carrón , M.J. Montero , M. Ramos , and I. Recio . Novel casein-derived peptides with antihypertensive activity. Int Dairy J 19: 566–573, 2009.
A.B. Garcia-Redondo , F.R. Roque , R. López-Fandiño , M. Miguel , and M. Salaices . Vascular effects of egg-derived peptides in resistance arteries from rats. Structure–activity relationship. J Sci Food Agric 90: 1988–1993, 2010.
N. Matoba , H. Usui , H. Fujita , and M. Yoshikawa . A novel antihypertensive peptide derived from ovalbumin induces nitric oxide-mediated vasorelaxation in an isolated SHR mesenteric artery. FEBS Lett 452: 181–184, 1999.
N. Matoba , Y. Yamada , H. Usui , R. Nakagiri , and M. Yoshikawa . Designing potent derivatives of ovokinin(2–7), an anti-hypertensive peptide derived from ovalbumin. Biosci Biotechnol Biochem 65: 736–739, 2001.
P. Scruggs , C.M. Filipeanu , J. Yang , J. Kang. Chang , and N.J. Dun . Interaction of ovokinin (2–7) with vascular bradykinin 2 receptors. Reg Pep 120: 85–91, 2004.
W. Maes , J. Van. Camp , V. Vermeirssen , M. Hemeryck , J.M. Ketelslegers , J. Schrezenmeir , P. Van. Oostveldt , and A. Huyghebaert . Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelial cells. Regul Pept 18: 105–109, 2004.
M. Miguel , M. Ramos , M.A. Aleixandre , and R. López-Fandiño . Antihypertensive peptides obtained from egg white proteins by enzymatic hydrolysis. Stability under simulated gastrointestinal digestion. J Agric Food Chem 54: 726–731, 2006.
M. Miguel , Y. Alvarez , R. López-Fandiño , M.J. Alonso , and M. Salaices . Vascular effects of peptides derived from egg white proteins. Reg Pep 140: 131–135, 2007.
Y. Yamada , D. Yamauchi , M. Yokoo , K. Ohinata , H. Usui , and M. Yoshikawa . A potent hypotensive pep-tide, novokinin, induces relaxation by AT2- and IP-receptor-dependent mechanism in the mesenteric artery from SHRs. Biosci Biotechnol Biochem 72: 257–259, 2008.
Y. Nakamura , N. Yamamoto , K.Y. Sakai , and T. Takano . Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci 78: 1253–1257, 1995.
M. Miguel , B. Muguerza , E. Sánchez , M.A. Delgado , I. Recio , M. Ramos , and M.A. Aleixandre . Changes in arterial blood pressure of milk fermented by Enterococcus faecalis CECT 5728 in spontaneously hypertensive rats. Br J Nutr 93: 1–9, 2005.
B. Muguerza , M. Ramos , E. Sánchez , M.A. Manso , M. Miguel , A. Aleixandre , M.A. Delgado , and I. Recio . Antihypertensive activity of milks fermented by Enterococcus faecalis strains isolated from raw milk. Int Dairy J 16: 61–69, 2006.
M. Miguel , R. López-Fandiño , M. Ramos , and M.A. Aleixandre . Long-term antihypertensive effect of egg white treated with pepsin in hypertensive rats. Life Sci 78: 2960–2966, 2006.
M. Miguel , M.M. Contreras , I. Recio , and A. Aleixandre . ACE-inhibitory and antihypertensive properties of a bovine casein hydrolysate. Food Chem 112: 211–214, 2009.
M. Miguel , J. Gómez-Ruiz , I. Recio , and A. Aleixandre . Changes in arterial blood pressure after single oral administration of milk-casein derived peptides. Mol Nutr Food Res 54: 1–6, 2010.
R. López-Fandiño , J. Otte , and J. Van. Camp . Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. Int Dairy J 16: 1277–1293, 2006.
K. Okamoto and K. Aoki . Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27: 282–293, 1963.
N.C. Trippodo and E.D. Frohlich . Similarities of genetic (spontaneous) hypertension in man and rat. Circ Res 48: 309–319, 1981.
J. Zicha and J. Kunes . Ontogenetic aspects of hypertension development: Analysis in the rat. Physiol Rev 79: 1227–1282, 1999.
R.D. Buñag . Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34: 279–282, 1973.
N.L. Nurminen , M. Sipola , H. Kaarto , A. Pihlanto-Leppälä , K. Piilola , R. Korpela , O. Tossavainen , H. Korhonne , and H. Vapaatalo . A-lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 66: 1535–1543, 2000.
D. Rousseau-Ralliard , F. Goriand , S. Tardivel , A. Lucas , F. Algaron , D. Mollé , V. Robert et al. Inhibitory effect of as1- and as2-casein hydrolysates on angiotensin I-converting enzyme in human endothelial cells in vitro, rat aortic tissue ex vivo, and renovascular hypertensive rats in vivo. J Dairy Sci 93: 2906–2921, 2010.
Y. Hata , M. Yamamoto , M. Ohni , K. Nakajim , Y. Nakamura , and T. Takano . A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 64: 767–771, 1996.
T. Kawasaki , E. Seki , K. Osajima , M. Yoshida , K. Asada , T. Matsui , and Y. Osajima . Antihypertensive effect of Valyl-tyrosine, a short chain peptide derived of sardine muscle hydrolyzate, on mild hypertensive subjects. J Hum Hypertens 14: 519–523, 2000.
L. Seppo , T. Jauhiainen , T. Poussa , and R. Korpela . A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77: 326–330, 2003.
R.R. Townsend , C.B. McFadden , V. Ford , and J.A. Cadeé . A randomized, double-blind, placebo controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am J Hypertens 17: 1056–1058, 2004.
S. Mizuno , K. Matsuura , T. Gotou , S. Nishimura , O. Kajimoto , M. Yabune , Y. Kajimoto , and N. Yamamoto . Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr 94: 84–91, 2005.
T. Jauhiainen , H. Vapaatalo , T. Poussa , S. Kyrönpalo , M. Rasmussen , and R. Korpela . Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 18: 1600–1605, 2005.
T. Jauhiainen , M. Ronnback , H. Vapaatalo , K. Wuolle , H. Kautiainen , and R. Korpela . Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. Int Dairy J 17: 1209–1211, 2007.
J.A. Cadee , C. Chang , C.W. Chen , C.N. Huang , S.L. Chen , and C.K. Wang . Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects. Am J Hypertens 20: 1–5, 2007.
A.H. Pripp . Effect of peptides derived from food proteins on blood pressure: A meta-analysis of randomized controlled trials. Food Nutr Res 52: 1641–1645, 2008.
J.Y. Xu , L.Q. Qin , P.Y. Wang , W. Li , and C. Chang . Effect of milk tripeptides on blood pressure: A metaanalysis of randomized controlled trials. Nutrition 24: 933–940, 2008.
T. Jauhiainen , M. Rönnback , H. Vapaatalo , K. Wuolle , H. Kautiainen , P.H. Groop , and R. Korpela . Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr 64: 424–431, 2010.
J.M. Geleijnse and M.F. Engberink , Lactopeptides and human blood pressure. Curr Opin Lipidol 21: 58–63, 2010.
H. Korhonen and A. Pihlanto . Food-derived bioactive peptides—Opportunities for designing future foods. Curr Pharm Des 9:1297–1308, 2003.
B.N. Ames , M.K. Shigenaga , and T.M. Hagen . Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci 90: 7915–7922, 1993.
G.M. Williams , M.J. Iatropoulus , and J. Whysner . Food Chem Toxicol 37: 1027–1038, 1999.
N. Gharavi , S. Haggarty , and A.O.S. El-Kady . Chemopreventive and carcinogenic effects of tert-butylhydroquinone and its metabolites. Curr Drug Metab 8: 1–7, 2007.
G. Cervato , R. Cazzola , and B. Cestaro . Studies on the antioxidant activity of milk caseins. Int J Food Sci Nutr 50: 291–296, 1999.
B. Hernández-Ledesma , A. Dávalos , B. Bartolome , and L. Amigo Preparation of antioxidant enzymatic hydrolysates from α-lactalbumin and β-lactoglobulin. Identification of active peptides by HPLC-MS/ MS. J Agric Food Chem 53: 588–593, 2005.
H.M. Chen , K. Muramoto , F. Yamauchi , and K. Nokihara . Antioxidant activity of designed peptides based on the antioxidative peptide isolated from digests of a soybean protein. J Agric Food Chem 44: 2619–2323, 1996.
B.F. Gibbs , A. Zougman , R. Masse , and C. Mulligan . Production and characterization of bioactive pep-tides from soy hydrolysate and soy-fermented food. Food Res Int 37: 123–131, 2004.
B.H. Kong and Y.L.L. Xiong . Antioxidant activity of zein hydrolysates in a liposome system and the possible mode of action. J Agric Food Chem 54: 6059–6068, 2006.
J. Parrado , E. Miramontes , M. Jover , J.F. Gutierrez , L. de Teran , and J. Bautista . Preparation of a rice bran extract with potential use as a functional food. Food Chem 98: 742–748, 2006.
N. Cumby , Y. Zhong , M. Naczk , and F. Shahidi . Antioxidant activity and water-holding capacity of canola protein hydrolysates. Food Chem 109: 144–148, 2008.
S. Sakanaka , Y. Tachibana , N. Ishihara , and L.R. Juneja . Antioxidant activity of egg-yolk protein hydrolysates in a linoleic acid system. Food Chem 86: 99–103, 2004.
A. Saiga , S. Tanabe , and T. Nishimura . Antioxidant activity of peptides obtained from porcine myofibrillar proteins by protease treatment. J Agric Food Chem 51: 3661–3667, 2003.
R. Amarowicz and F. Shahidi . Antioxidant activity of peptide fractions of capelin protein hydrolysates. Food Chem 58: 355–359, 1997.
H.C. Wu , H.M. Chen , and C.Y. Shiau . Free amino acids and peptides as related to antioxidant properties in protein hydrolysates of mackerel (Scomber austriasicus). Food Res Int 36: 949–957, 2003.
S.Y. Jun , P.J. Park , W.K. Jung , and S.K. Kim . Purification and characterization of an antioxidative peptide from enzymatic hydrolysate of yellowfin sole (Limanda aspera) frame protein. Eur Food Res Technol 219: 20–26, 2004.
J.Y. Je , P.J. Park , and S.K. Kim . Antioxidant activity of a peptide isolated from Alaska Pollack (Theragra chalcogramma) frame protein hydrolysate. Food Res Int 38: 45–50, 2005.
A. Bougatef , M. Hajji , R. Balti , I. Lassoued , Y. Triki-Ellouz , and M. Nasri . Antioxidant and free radical-scavenging activities of smooth hound (Mustelus mustelus) muscle protein hydrolysates obtained by gastrointestinal proteases. Food Chem 114: 1198–1205, 2009.
A. Bougatef , N. Nedjar-Arroume , L. Manni , R. Ravallec , A. Barkia , D. Guillochon , and M. Nasri . Purification and identification of novel antioxidant peptides from enzymatic hydrolysates of sardinelle (Sardinella aurita) by-products proteins. Food Chem 118: 559–565, 2010.
A. Pihlanto . Antioxidant peptides derived from milk proteins. Int Dairy J 16: 1306–1314, 2006.
B. Hernández-Ledesma , L. Amigo , I. Recio , and B. Bartolomé . ACE-inhibitory and radical-scavenging activity of peptides derived from β-lactoglobulin f(19–25). Interactions with ascorbic acid. J Agric Food Chem 55: 3392–3397, 2007.
E.A. Pena-Ramos , Y.L. Xiong , and G.E. Arteaga . Fractionation and characterisation for antioxidant activity of hydrolysed whey protein. J Sci Food and Agric 84: 1908–1918, 2004.
K.M. Chan and E.A. Decker . Endogenous skeletal muscle antioxidants. Crit Rev Food Sci Nutr 34: 403–426, 1994.
H.M. Chen , K. Muramoto , F. Yamauchi , K. Fujimoto , and K. Nokihara . Antioxidative properties of histidine-containing peptides designed from peptide fragments found in the digests of a soybean protein. J Agric Food Chem 46: 49–53, 1998.
L.M. Magalhaes , M. Santos , M.A. Segundo , S. Reis , and J.L.F.C. Lima . Flow injection based methods for fast screening of antioxidant capacity. Talanta 77: 1559–1566, 2009.
M.M. Contreras , B. Hernández-Ledesma , L. Amigo , P.J. Martín-Álvarez , and I. Recio , Production of antioxidant hydrolyzates from a whey protein concentrate with thermolysin: Optimization by response surface methodology. LWT-Food Sci Technol 44: 9–15, 2011.
L. Zhang , J.R. Li , and K.Q. Zhou . Chelating and radical scavenging activities of soy protein hydrolyzates prepared from microbial proteases and their effect on meat lipid peroxidation. Bioresour Technol 101: 2084–2089, 2010.
J.J. Jensen , H. Abrahamsen , H.K. Maehre , and E.O. Elveoll . Changes in antioxidative capacity of saithe (Pollachius virens) and shrimp (Pandalus borealis) during in vitro digestion. J Agric Food Chem 57: 10928–10932, 2009.
A.G.P. Samaranayaka , and E.C.Y. Li-Chan , Autolysis-assisted production of fish protein hydrolyzates with antioxidant properties from Pacific hake (Merluccius productus). Food Chem 107: 768–776, 2008.
B. Ou , M. Woodill-Hampsch , and R.L. Prior , Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem 49: 4619–4626, 2001.
C. Beermann , M. Euler , J. Herzberg , and B. Stahl . Antioxidative capacity of enzymatically released pep-tides from soybean protein isolate. Eur Food Res Technol 229: 637–644, 2009.
B. Hernández-Ledesma , C.C. Hsieh , and B.O. de Lumen . Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun 186: 127–134, 2010.
X.Y. Tang , Z.Y. He , Y.F. Dai , Y.L.L. Xiong , M.Y. Xie , and J. Chen . Peptide fractionation and free radical scavenging activity of zein hydrolysate. J Agric Food Chem 58: 587–593, 2010.
A.P. Adebiyi , A.O. Adebiyi , J. Yamashita , T. Ogawa , and K. Muramoto . Purification and characterization of antioxidative peptides derived from rice bran protein hydrolyzates. Eur Food Res Technol 228: 553–563, 2009.
J.A. Gómez-Ruiz , I. López-Expósito , A. Pihlanto , M. Ramos , and I. Recio . Antioxidant activity of ovine casein hydrolysates. Identification of active peptides by HPLC-MS/MS. Eur Food Res Technol 227: 1061–1067, 2008.
S. Raghavan , H.G. Kristinsson , and C. Leeuweburgh . Radical scavenging and reducing ability of tilapia (Oreochomis niloticus) protein hydrolysates. J Agric Food Chem 56: 10359–10367, 2008.
L. You , M. Zhao , J.M. Regenstein , and J. Ren . Changes in the antioxidant activity of loach (Misgurnus anguillicaudatus) protein hydrolyzates during a simulated gastrointestinal digestion. Food Chem 120: 810–816, 2010.
V. Roginsky and E.A. Lissi . Review of methods to determine chain breaking antioxidant activity in food. Food Chem 92: 235–254, 2005.
M.J.T.J. Arts , G.R.M.M. Haenen , H. Voss , and A. Bast . Antioxidant capacity of reaction products limits the applicability of the Trolox Equivalent Antioxidant Capacity (TEAC) assay. Food Chem Toxicol 42: 45–49, 2004.
M.B. Arnao . Some methodological problems in the determination of antioxidant activity using chromogen radicals: A practical case. Trends Food Sci Technol 11: 419–421, 2000.
L.K. MacDonald-Wicks , L.G. Wood , and M.L. Garg . Methodology for the determination of biological antioxidant capacity in vitro: A review. J Sci Food Agric 86: 2046–2056, 2006.
K. Suetsuna , H. Ukeda , and H. Ochi . Isolation and characterization of free radical scavenging activities of peptides derived from casein. J Nutr Biochem 11: 128–131, 2000.
B. Li , F. Chen , X. Wang , B.P. Ji , and Y.N. Wu . Isolation and identification of antioxidative peptides from porcine collagen hydrolysate by consecutive chromatography and electrospray ionization-mass spectrometry. Food Chem 102: 1135–1143, 2008.
G.T. Chen , L. Zhao , L.Y. Zhao , T. Cong , and S.F. Bao . In vitro study on antioxidant activities of peanut protein hydrolysate. J Sci Food Agric 87: 357–362, 2007.
Y.C. Chen , H.S. Chang , C.T. Wang , and F.Y. Cheng . Antioxidative activities of hydrolysates from duck egg white using enzymatic hydrolysis. Asian Aust J Anim Sci 22: 1587–1593, 2009.
X.P. Dong , B.W. Zhu , H.X. Zhao , D.Y. Zhou , H.T. Wu , J.F. Yang , D.M. Li , and Y. Murata . Preparation and in vitro antioxidant activity of enzymatic hydrolysates from oyster (Crassostrea talienwhannensis) meat. Int J Food Sci Technol 45: 975–984, 2010.
S.B. Zhang , Z. Wang , S.Y. Xu , and X.F. Gao . Purification and characterization of a radical scavenging peptide from rapeseed protein hydrolysates. J Am Oil Chem Soc 86: 959–966, 2009.
C.H. Tang , J. Peng , D.W. Zhen , and Z. Chen . Physicochemical and antioxidant properties of buckwheat (Fagopyrum esculentum Moench) protein hydrolysates. Food Chem 115: 672–678, 2009.
I.F.F. Benzie , W.Y. Chung , and J.J. Strain . Antioxidant (reducing) efficiency of ascorbate in plasma is not affected by concentration. J Nutr Biochem 10: 146–150, 1999.
P. Phanturat , S. Benjakul , W. Visessanguan , and S. Roytrakul . Use of pyloric caeca extract from bigeye snapper (Priacanthus macracanthus) for the production of gelatine hydrolysate with antioxidant activity. LWT-Food Sci Technol 43: 86–97, 2010.
C. Hu , Y. Zhang , and D.D. Kitts . Evaluation of antioxidant and prooxidant activity of bamboo Phyllostachys nigra var. henonis leaf extract in vitro. J Agric Food Chem 48: 3170–3176, 2000.
N. Katsube , H. Tabata , Y. Ohta , Y. Yamasaki , E. Anuurad , K. Shiwaku , and Y. Yamane . Screening for antioxidant activity in edible plant products: Comparison of low-density lipoprotein oxidation assay, DPPH radical scavenging assay, and Folin–Ciocalteu assay. J Agric Food Chem 52: 2391–2396, 2004.
F. Shahidi , C.M. Liyana-Pathirana , and D.S. Wall . Antioxidant activity of white and black sesame seeds and their hull fractions. Food Chem 99: 478–483, 2006.
P. Chumark , P. Khunawat , Y. Sanvarinda , S. Phornchirasilp , N.P. Morales , L. Phivthong-ngam , P. Ratanachamong , S. Srisawat , and K.U.S. Pongrapeeporn . The in vitro and ex-vivo antioxidant properties, hypolipidaemic and antiatherosclerotic activities of water extract of Moringa oleifera Lam. leaves. J Ethnopharmacol 116: 439–446, 2008.
E.Y. Park , M. Morimae , Y. Matsumura , Y. Nakamura , and K. Sato . Antioxidant activity of some protein hydrolysates and their fractions with different isoelectric points. J Agric Food Chem 56: 9246–9251, 2008.
R. Slizyte , R. Mozuraityte , O. Martínez-Álvarez , E. Falch , M. Fouchereau-Peron , and T. Rustard . Functional, bioactive and antioxidant properties of hydrolysates obtained from cod (Gadus morrhua) backbones. Process Biochem 44: 668–677, 2009.
J. Mamelona , R. Saint-Louis , and E. Pelletier . Nutritional composition and antioxidant properties of protein hydrolysates from echinoderm byproducts. Int J Food Sci Technol 45: 147–154, 2010.
G.J. Handelman , G. Cao , M.F. Walter , Z.D. Nightingale , G.L. Paul , R.L. Prior , and J.B. Blumberg . Antioxidant capacity of oat (Avena sativa L.) extracts. 1. Inhibition of low-density lipoprotein oxidation and oxygen radical absorbance capacity. J Agric Food Chem 47: 4888–4893, 1999.
S. Cenesiz , A.K. Devrim , U. Kamber , and M. Sozmen . The effect of kefir on glutathione (GSH), malondialdehyde (MDA) and nitric oxide (NO) levels in mice with colonic abnormal crypt formation (ACF) induced by azoxymethane (AOM). Dtsch Tierarztl Wochenschr 115: 15–19, 2008.
M.A. Manso , M. Miguel , J. Even , R. Hernandez , M.A. Aleixandre , and R. López-Fandiño . Effect of the long-term intake of an egg white hydrolysate on the oxidative status and blood lipid profile of spontaneously hypertensive rats. Food Chem 109: 361–367, 2008.
D. Young , M.Z. Fan , and Y. Mine . Egg yolk peptides up-regulate glutathione synthesis and antioxidant enzyme activities in a porcine model of intestinal oxidative stress. J Agric Food Chem 58: 7624–7633, 2010.
I. Ginsburg . The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 110: 753–770, 2002.
A. Linde , D. Mosier , F. Blecha , and T. Melgarejo . Innate immunity and inflammation. New frontiers in comparative cardiovascular pathology. Cardiovasc Res 73: 26–36, 2007.
I. López-Expósito and I. Recio . Antibacterial activity of peptides and folding variants from milk proteins. Int Dairy J 16: 1294–1305, 2006.
I. López-Expósito , and I. Recio , Protective effect of milk peptides: Antibacterial and antitumor properties. Adv Exp Med Biol 606:271–293, 2008.
M. Hayes , R.P. Ross , G.F. Fitzgerald , C. Hill , and C. Stanton . Casein-derived antimicrobial peptides generated by Lactobacillus acidophilus DPC6026. Appl Environ Microbiol 72: 2260–2264, 2006.
C. Liepke , H.D. Zucht , W.G. Forssman , and L. Ständker , Purification of novel peptide antibiotics from human milk. J Chromatogr B 752: 369–377, 2001.
M. Enrique , P. Manzanares , Y. María , M. Martínez , S. Valles , and J.F. Marcos . Selectivity and antimicrobial action of bovine lactoferrin derived peptides against wine lactic acid bacteria. Food Microbiol 26: 340–346, 2009.
I. López-Expósito , M.A. Manso , R. López-Fandiño , and I. Recio . Activity against Listeria monocytogenes of human milk during lactation: A preliminary study. J Dairy Res 75: 24–29, 2008.
H.L. Chen , C.C. Yeng , C.Y. Lu , C.H. Yu , and C.M. Chen . Synthetic porcine lactoferricin with a 20-residue peptide exhibits antimicrobial activity against Escherichia coli, Staphylococcus aureus and Candida albicans. J Agric Food Chem 54: 3277–3282, 2006.
I. Recio and S. Visser . Identification of two distinct antibacterial domains within the sequence of bovine alpha(s2)-casein. Biochim Biophys Acta 1428: 314–326, 1999.
M.I.A. van der Kraan , J. Groenink , K. Nazmi , E.C.I. Veerman , J.G.M. Bolscher , and A.V. Nieuw Amerongen , Lactoferrampin: A novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25: 177–183, 2004.
A. Pihlanto-Leppälä , P. Marnila , L. Hubert , T. Rokka , H.J.T. Korhonen , and M. Karp , The effect of α-lactalbumin and β-lactoglobulin hydrolysates on the metabolic activity of Escherichia coli JM103. J Appl Microbiol 87: 540–545, 1999
W.M. Brück , G. Gaverholt , and G.R. Gibson , Use of batch culture and two-stage continuous culture system to study the effect of supplemental α-lactalbumin and glycomacropeptide on mixed populations of human gut bacteria. FEMS Microbiol Ecol 41: 231–237, 2002.
L.H. Vorland , H. Ulvatne , J. Andersen , H.H. Haukland , O. Rekdal , J.S. Svendsen , and T.J. Gutteberg . Antibacterial effects of lactoferricin B. Scand J Infect Dis 31: 179–184, 1999.
Y. Nakasone , A. Adjei , M. Yoshise , K. Yamauchi , M. Takase , K. Yamauchi , S. Shimamura , and S. Yamamoto . Effect of dietary lactoferricin on the recovery of mice infected with methicillin-resistant Staphylococcus aureus. Abstract Annual Meeting of the Japanese Society of Nutritional Food Science (in Japanese) p. 50, 1994.
T. Isamida , T. Tanaka , Y. Omata , K. Yamauchi , K. Shimazaki , and A. Saito . Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J Vet Med Sci 60: 241–244, 1998.
H. Kuwata , T.T. Yip , M. Tomita , and T.W. Hutchens . Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim Biophys Acta 1429: 129–141, 1998
H. Kuwata , T.T. Yip , K. Yamauchi , S. Teraguchi , H. Hayasawa , M. Tomita , and T.W. Hutchens . The survival of ingested lactoferrin in the gastrointestinal tract of adult mice. Biochem J 334: 321–323, 1998.
S. Kawaguchi , T. Hayashi , H. Masano , K. Okuyama , T. Suzuki , and K. Kawase . Effect of lactoferrinenriched infant formula on low birth weight infants. Shuusnakiigaku 19: 125–130, 1989 (in Japanese).
F. Di. Mario , G. Aragona , N. Dal. Bo , G.M. Cavestro , L. Cavallaro , V. Iori , G. Comparato , G. Leandro , A. Pilotto , and A. Franze . Use of bovine lactoferrin for Helicobacter eradication. Digest Liver Dis 35: 706–710, 2003.
M. Tomita , H. Wakabayashi , K. Yamauchi , S. Teraguchi , and H. Hayasawa . Bovine lactoferrin and lactoferricin derived from milk: Production and applications. Biochem Cell Biol 80: 109–112, 2002.
K. Marshall . Therapeutic applications of whey protein. Altern Med Rev 9: 136–156, 2004.
E. Lahov and W. Regelson . Antibacterial and immunostimulating casein-derived substances from milk: Casecidin, isracidin peptides. Fed Chem Toxicol 34: 131–145, 1996.
G.A. Biziulevicius , V. Zukaite , T. Normatiene , G. Biziuleviciene , and I. Arestov . Non-specific immunity-enhancing effects of tryptic casein hydrolysate versus Fermosob for treatment/prophylaxis of newborn calf colibacillosis. FEMS Immunol Med Microbiol 39: 155–161, 2003.
C.H. Florén , S. Chinenye , L. Elfstrand , C. Hagman , and I. Ihse . Coloplus, a new product based on bovine colostrums, alleviates HIV-associated diarrhoea. Scan J Gastroenterol 41: 682–686, 2006.
H. Teschemacher . Opioid receptor ligands derived from food proteins. Curr Pharm Design 9:1331–1344, 2003.
V. Schusdziarra , R. Schick , A. de la Fuente , A. Holland , V. Brantl , and E.F. Pfeiffer . Effect of β-casomorphins on somatostatin release in dogs. Endocrinology 112: 1948–1951, 1983.
V. Schusdziarra , R. Schick , A. de la Fuente , J. Specht , M. Klier , V. Brantl , and E.F. Pfeiffer . Effect of β-casomorphins and analogs on insulin release in dogs. Endocrinology 112: 885–889, 1983.
M. Brandsch , P. Brust , K. Neubert , and A. Ermisch . β-Casomorphins—Chemical signals of intestinal transport systems. In V. Brantl and H. Teschemacher (eds), β-Casomorphins and Related Peptides: Recent Developments. Weinhem, VCH, 1994, pp. 207–219.
H. Daniel , M. Vohwinkel , and G. Rehner . Effect of casein and β-casomorphins on gastrointestinal motility in rats. J Nutr 120: 252–257, 1990.
S. Zoghbi , A. Trompette , J. Claustre , M.E. Homsi , J. Garzón , G. Jourdan , J.Y. Scoazec , and P. Plaisancié . β-Casomorphin-7 regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. Am J Physiol Gastrointest Liver Physiol 290: G1105–G1113, 2006.
H. Meisel and R.J. FitzGerald . Opioid peptides encrypted in intact milk protein sequences. Br J Nutr 84: S27–S31, 2000.
D.F. Mierke , G. Nöβner , P.W. Schiller , and M. Goodman . Morphiceptin analogs containing 2-aminocyclopentane carboxylic-acid as a peptidomimetic for proline. Int J Peptide Res 35: 34–45, 1990
H. Meisel . Biochemical properties of regulatory peptides derived from milk proteins. Biopolymers 43: 119–128, 1997.
C. Zioudrou , R.A. Streaty , and W.A. Klee . Opioid peptides derived from food proteins. J Biol Chem 254: 2446–2449, 1979.
P. Holzer . Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361: 192–195, 2004.
J. Hughes , H.W. Kosterlitz , and F.M. Leslie . Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br J Pharmacol 53: 371–381, 1975.
A. Goldstein and A. Naidu . Multiple opioid receptors: Ligand selectivity profiles and binding sites signatures. Mol Pharmacol 36: 265–272, 1989.
C. Defilippi , E. Gómez , V. Charlin , and C. Silva . Inhibition of small intestinal motility by casein: A role of beta casomorphins? Nutrition 11: 751–754, 1995.
V. Schusdziarra , A. Holland , R. Schick , A. de la Fuente , M. Klier , V. Maier , V. Brantl , and E.F. Pfeiffer . Modulation of post-prandial insulin release by ingested opiate-like substances in dogs. Diabetologia 24: 113–116, 1983.
J. Pupovac and G.H. Anderson . Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J Nutr 132: 2775–2780, 2002.
R. Mansfeld , J. Kautni , E. Grunert , V. Brantl , and W. Jöchle . In F. Nyberg and V. Brantl (ed.), Casomorphins and Related Peptides. Uppsala,Fyris-Tryck, 1990, pp. 105–108.
S. Yang , J. Yunden , S. Sonoda , N. Doyama , A.W. Lipkowski , Y. Kawamura , and M. Yoshikawa . Rubiscolin, a δ selective opioid peptide derived from plant Rubisco. FEBS Lett 509: 213–217, 2001.
H. Ijäs , M. Collin , P. Finckenberg , A. Pihlanto-Leppälä , H. Korhonen , R. Korpela , H. Vapaatalo , and M.L. Nurminen . Antihypertensive opioid-like milk peptide α-lactorphin: Lack of effect on behavioural tests in mice. Int Dairy J 14: 201–205, 2004
D. Sánchez , M. Kassan , M.M. Contreras , R. Carrón , I. Recio , M.J. Montero , and M.A. Sevilla . Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. Pharmacol Res 63: 398–404, 2011.
E. Schulte-Frohlinde , R. Schimid , V. Brantl , and V. Schusdziarra . In V. Brantl and H. Teschemacher (eds), Casomorphins and Related Peptides: Recent Developments. New York, VCH, 1994, pp. 155–160.
J.E. Morley , A.S. Levine , T.Yamada, R.L. Gebhard , W.F. Prigge , R.B. Shafer , F.C. Goetz , and S.E. Silvis . The effect of exorphins on gastrointestinal function, hormonal release and appetite. Gastroenterology 84: 1517–1523, 1983.
O. Mellander . The physiological importance of the casein phosphopeptide calcium salts. II. Peroral calcium dosage of infants. Acta Soc Med Ups 55: 247–255, 1950.
C. Megias , J. Pedroche , M.M. Yust , J. Giron-Calle , M. Alaiz , F. Milan , and J. Vioque . Affinity purification of copper chelating peptides from chickpea protein hydrolysates. J Agric Food Chem 55: 6509–6514, 2007.
L.M. Gaetke and C.K. Chow . Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicol 189: 147–163, 2003.
E.C. Reynolds . The prevention of subsurface demineralisation of bovine enamel and change in plaque composition by casein in and intraoral model. J Dental Res 66: 1120–1127, 1987.
H. Otani , Y. Kihara , and M. Park . The immunoenhancing property of dietary casein phosphopeptide preparation in mice. Food Agric Immunol 12: 165–173, 2000.
G.E. Vegarud , T. Langsrud , and C. Svenning . Mineral-binding milk proteins and peptides; occurrence, biochemical and technological characteristics. Br J Nutr 84: S91–S98, 2000.
B. Chabance , P. Marteau , J.C. Rambaud , D. Migliore-Samour , M. Boynard , P. Perrotin , R. Guillet , P. Jollés , and A.M. Fiat . Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 80: 155–165, 1998.
H. Meisel , H. Bernard , S. Fairweather-Tait , R.J. FitzGerald , R. Hartmann , C.N. Lane , D. McDonagh , B. Teucher , and J.M. Wal . Detection of caseinophosphopeptides in the distal ileostomy fluid of human subjects. Br J Nutr 89: 351–359, 2003.
H. Meisel and R.J. FitzGerald . Biofunctional peptides from milk proteins: Mineral binding and cytomodulatory effects. Curr Pharm Des 9: 1289–1295, 2003.
M. Juillerat , R. Baechtler , R. Berrocal , S. Chanton , J.C. Scherz , and R. Jost . Trypic phosphopeptide from whole casein. 1. Preparation and analysis by fast protein liquid chromatography. J Dairy Res 56: 603–611, 1989.
Y. Hirai , E.A. Permyakov , and L.J. Berliner . Protelytic digestion of α-lactalbumin: Physiological implications. J Prot Chem 11: 51–57, 1992.
H. Kawakami , S. Dosako , and I. Nakajima . Effect of lactoferrin on iron solubility under neutral conditions. Biosci Biotech Biochem 57: 1376–1377, 1993.
E. Dufour , M. Dalgarrondo , and T. Haertlé . Limited proteolysis of β-lactoglobulin using thermolysin. Effects of calcium and the outcome of proteolysis. Int J Biol Macromol 16: 37–41, 1994.
E.C. Reynolds , P.F. Riley , and N.J. Adamson . A selective precipitation purification procedure for multiple phosphoseryl-containing peptides and methods for their identification. Anal Biochem 217: 277–284, 1994.
E. Schlimme and H. Meisel . Bioactive peptides derived from milk protein. Structural, physiological and analytical aspects. Nahrung 39: 1–20, 1995.
F. Gaucheron , M.H. Famelart , and Y. Le Graet . Iron-supplement caseins: Preparation, physiochemical characterization and stability. J Dairy Res 63: 233–243, 1996.
Y. Dohi , K. Iwami , K. Yonemasu , and T. Moriyama . Two proteins with gamma-carboxyglutamic acid in frog bone: Isolation and comparative characterization. Biochim Biophys Acta 915: 378–334, 1987.
Y.J. Jeon , H.G. Byun , and S.K. Kim . Improvement of functional properties of cod frame protein hydrolysates using ultrafiltration membranes. Process Biochem 35: 471–478, 2000.
Q.O.Q. Hoang , F. Sicheri , A.J. Howard , and D.S.C. Yang . Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 425: 977–980, 2003.
W.K. Jung , P.J. Park , H.G. Byun , S.H. Moon , and S.K. Kim . Preparation of hoki (Johnius belengerii) bone oligophosphopeptide with a high affinity to calcium by carnivorous intestine crude proteinase Food Chem 91: 333–340, 2005.
E.C. Reynolds . Anticariogenic casein phosphopeptides. Protein Pept Lett 6: 295–303, 1999.
E.A. Warner , A.D. Kanekanian , and A.T. Andrews . Bioactivity of milk proteins: 1. Anticariogenicity of whey proteins. Int J Dairy Technol 54: 151–153, 2001.
K.J. Cross , N.L. Huq , J.E. Palamara , J.W. Perich , and E.C. Reynolds . Physicochemical characterization of casein phosphopeptide-amorphous calcium phosphate nanocomplexes. J Biol Chem 280: 15362–15369, 2005.
A. Aziz-Alrahman . An ion exchange separation-atomic absorption spectrophotometric method for the determination of microgram quantities of copper, iron and zinc in infant milk formula: Powder form. Anal Lett 27: 411–428, 1994.
D.D. Miller , B.R. Schricker , R.R. Rasmussen , and D. Van , Campen An in vitro method for estimation of iron availability from meals. Am J Clin Nutr 34: 2248–2256, 1981.
F.M. Clydesdale and D.B. Nadeau . Solubilization of iron in cereals by milk and nilk fractions. Cereal Chem 61: 330–335, 1984.
G. Kontoghiorghes . Iron mobilisation from lactoferrin by chelators at physiological pH. Biochim Biophys Acta 882: 267–270, 1986.
I.V. Gutch . Determination of chelating agents in fertilisers by ion chromatography. J Chromatogr 671: 359–365, 1994.
E.K. Amine and D.M. Hegsted . Effect of dietary carbohydrates and fats on inorganic iron absorption. J Agric Food Chem 23: 204–208, 1975.
A. Sanyal , J.I. Hirsch , and E.W. Moore . Premicellar taurocholate avidly binds ferrous (Fe2+) iron: A potential physiological role for bile salts in iron absorption. J Lab Clin Med 116: 76–86, 1990.
S.J. Fairweather-Tait , A. Minihane , J. Eagles , L. Owen , and H.M. Crews . Rare earth elements as nonabsorbable fecal markers in studies of iron absorption. Am J Clin Nutr 65: 970–976, 1997.
M. Pinto , S. Robine-Leon , M.D. Appay , M. Kedinger , N. Triadou , E. Dussaulx , B. Lacroix et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47: 323–330, 1983.
C. Ekmekcioglu . A physiological approach for preparing and conducting intestinal bioavailability studies using experimental systems. Food Chem 76: 225–230, 2002.
S. Bouhallab and D. Bouglé . Biopeptides of milk: Casein phosphopeptides and mineral bioavailability. Rep Nutr Dev 44: 493–498, 2004.
M. Narva , J. Halleen , K. Väänänen , and R. Korpela . Effects of Lactobacillus helveticus fermented milk on bone cells in vitro. Life Sci 75: 1727–1734, 2004.
M. Jovaní , R. Barberá , R. Farré , and E. Martín de Aguilera . Calcium, iron and zinc uptake from digests of infant formulas by Caco-2 cells. J Agric Food Chem 49: 3480–3485, 2001.
H. Meisel . Bioactive peptides from milk proteins: A perspective for consumers and producers. Australian J Dairy Technol 56: 83–92, 2001.
D. Erba , S. Ciappellani , and G. Testolin . Effect of the ratio of casein phosphopeptides to calcium (w/w) on passive calcium transport in the distal small intestine of rats. Nutrition 18: 743–746, 2002.
Y.S. Lee , Y. Noguchi , and H. Naito . Phosphopeptides and soluble calcium in the small intestine of rats given a casein diet. Br J Nutr 43: 457–467, 1980.
H. Tsuchita , I. Sekiguchi , and T. Kuwata . Comparison of the effects of whey mineral complexes on bone metabolism in male growing rats. J Nutr Sci Vitaminol 39: 473–487, 1993.
H.R. Knapp , I.A. Reilly , P. Alessandrini , and G.A. FitzGerald . In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1314: 937–942, 1986.
A. Atanassov and B. Tchorbanov . Synthetic and natural peptides as antithrombotic agents—A view on the currents development. Biotechnol Biotec Eq 23: 1109–1114, 2009.
G.A. Marguerie , E.F. Plow , and T.S. Edgington . Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 254: 5357–5363, 1979.
M. Kloczewiak , S. Timmons , T.J. Lukas , and J. Hawiger . Platelet receptor recognition site on human fibrinogen. Synthesis and structure–function relationship of peptides corresponding to the carboxyterminal segment of the γ-chain. Biochemistry 23: 1767–1774, 1984.
P. Jollés , S. Lévy-Toledano , A.M. Fiat , C. Soria , D. Gillensen , A. Thomaidis , F.W. Dunn , and J. Caen . Analogy between fibrinogen and casein. Effect of an undecapeptide isolated from k-casein on platelet function. Eur J Biochem 158: 379–382, 1986.
R.J. Shebuski , D.E. Berry , D.B. Bennett , T. Romoff , B.L. Storer , F. Ali , and J. Samanen . Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as a antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost 61: 183–188, 1989.
A.M. Fiat , D. Migliore-Samour , and P. Jollés . Biologically active peptides from milk proteins with emphasis on two examples concerning antithrombotic and immunomodulating activities. J Dairy Sci 76: 301–310, 1993.
C. Bal dit Solier, L. Drouet , G. Pignaud , C. Chevalier , J.P. Caen , A.M. Fiat , C. Izquierdo , and P. Jollés . Effect of k-casein derived peptides on platelet aggregation and on thrombous formation in the guinea pig. Thromb Res 81: 427–437, 1996.
K.J. Rutherfurd and H.S. Gill . Peptides affecting coagulation. Br J Nutr 84: S99–S102, 2000.
M.A. Manso , C. Escudero , M. Alijo , and R. López-Fandiño . Platelet aggregation inhibitory activity of bovine, ovine and caprine k-casein macropeptides and their tryptic hydrolysates. J Food Protect 65: 1992–1996, 2002.
B. Chabance , P. Jolles , C. Izquierdo , E. Mazoyer , C. Francoual , L. Drouet , and A.M. Fiat . Characterization of an antithrombotic peptide from kappa-casein in newborn plasma after milk ingestion. Br J Nutr 73: 583–590, 1995.
K.A. Lee and S.H. Kim . SSGE and DEE, new peptides isolated from a soy protein hydrolysate that inhibit platelet aggregation. Food Chem 90: 389–393, 2005.
E. Mazoyer , S. Lévy-Toledano , F. Rendu , L. Hermant , H. Lu , A.M. Fiat , P. Jollés , and J.P. Caen . KRDS, a new peptide derived from lactotransferrin inhibits platelet aggregation and release reaction. Eur J Biochem 194: 43–49, 1990.
L. Drouet , C. Bal , d.i.t. Sollier , M. Cissé , G. Pignaud , E. Mazoyer , A.M. Fiat , P. Jollés , and J.P. Caen . The antithrombotic effect of KRDS, a lactotransferrin peptide, compared with RGDS. Nouv Rev Fr Hematol 32: 59–62, 1990.
M. Shimizu , N. Sawashita , F. Morimatsu , J. Ichikawa , Y.Taguchi, Y. Ijiri , and J. Yamamoto . Antithrombotic papain-hydrolyzed peptides isolated from pork meat. Thromb Res 123: 753–757, 2009.
W.B. Kannel , W.P. Castelli , T. Gordon , and P.M. McNamara . Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 74: 1–12, 1971.
T. Gordon and W.B. Kannel . Preamture mortality from coronary heart disease: The Framinghan Heart Study. JAMA 215: 1617–1625, 1971.
K.M. Anderson , W.P. Castelli , and D. Levy . Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 257: 2176–2180, 1987.
W.M. Verschuren , D.R. Jacobs , B.P. Bloemberg , D. Kromhout , A. Menotti , C. Aravanis , H. Blackburn , R. Buzina , A.S. Dontas , and F. Fidanza . Serum total cholesterol and long-term coronary heart disease mortality in different cultures: 25-year follow-up of the Seven Countries Study. JAMA 274: 131–136, 1995.
A. Yashiro , S. Oda , and M. Sugano . Hypocholesterolemic effect of soybean protein in rats and mice after peptic digestion. J Nutr 115: 1325–1336, 1985.
X. Zhang and A. Beynen . Influence of dietary fish proteins on plasma and liver cholesterol concentrations in rats. Br J Nutr 69: 767–777, 1993.
M.F. Wang , S. Yamamoto , H.M. Chung , S. Miyatini , M. Mori , T. Okita , and M. Sugano . Antihypercholesterolemic effect of undigested fraction of soybean protein in young female volunteers. J Nutr Sci Vitaminol 41: 187–195, 1995.
C. Kirana , P.F. Rogers , L.E. Bennett , M.Y. Abeywardena , and G.S. Patten . Naturally derived micelles for rapid in vitro screening potential cholesterol-lowering bioactives. J Agric Food Chem 5: 4623–4627, 2005.
I. Holme . An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 82: 1916–1924, 1990.
J.E. Rossouw , B. Lewis , and B.M. Rifkind . The value of lowering cholesterol after myocardial infarction. N Engl J Med 323: 1112–1119, 1990.
G.N. Levine , J.F. Keany , and J.A. Vita . Medical Progress. Cholesterol reduction in cardiovascular disease. N Engl J Med 332: 512–521, 1995.
A.M. Gotto . Results of recent large cholesterol-lowering trials and their implications for clinical management. Am J Cardiol 79: 1663–1666, 1997.
S. Nagaoka , Y. Futamura , K. Miwa , T. Awano , K. Yamauchi , Y. Kanamaru , K. Tadashi , and T. Kuwata . Identification of novel hypocholesterolemic peptides derived from bovine milk β-lactoglobulin. Biochem Biophys Res Commun 281: 11–17, 2001.
J.J. Pins and J.M. Keenan . Effects of whey peptides on cardiovascular disease risk factors. J Clin Hypertens 8: 775–782, 2006.
F. Zhong , J. Liu , J. Ma , and C.F. Shoemaker . Preparation of hypocholesterol peptides from soy protein and their hypocholesterolemic effect in mice. Food Res Int 40: 661–667, 2007.
F. Zhong , X. Zhang , J. Ma , and C.F. Shoemaker . Fractionation and identification of a novel hypocholesterolemic peptide derived from soy protein Alcalase hydrolysates. Food Res Int 40: 756–762, 2007.
K.C. Huang . The Pharmacology of Chinese Herbs. CRC Press, Boca Raton, FL, 1993, pp 99–109.
F. Shahidi and Y. Zhong . Bioactive peptides. J AOAC Int 91: 914–931, 2008.
E. Ros . Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 151: 357–379, 2000.
J.A. Story and D. Kritchevsky . Comparison of the binding of various bile acids and bile salts in vitro by several types of fiber. J Nutr 106: 1292–1294, 1976.
K. Iwami , K. Sakakibara , and F. Ibuki . Involmement of post-digestion hydrophobic peptides in plasma cholesterol-lowering effect of dietary plant-proteins. Agric Biol Chem 50: 1217–1222, 1986.
A. Bruusgaard , H. Srensen , C.C. Gilhuus-Moe , and B.A. Skalhegg . Bile acid determination with different preparations of 3alpha-hydroxysteroid dehydrogenase. Clin Chim Acta 77: 387–395, 1977.
A. Malchow-Moller , S. Arffmann , N.F. Larusso , and E. Krag Enzymatic determination of total 3 alpha-hydroxy bile acids in faeces. Validation in healthy subjects of a rapid method suitable for clinical routine purpose. Scand J Gastroeneterol 17: 331–333, 1982.
F.J. Field , E. Albright , and S. Mathur . Regulation of cholesterol esterification by micellar cholesterol in CaCo-2 cells. J Lipid Res 28: 1057–1066, 1987.
M.C. Ramirez-Tortosa , M.D. Mesa , M.C. Aguilera , J.L. Quiles , L. Baró , C.L. Ramirez-Tortosa , E. Martinez-Victoria , and A. Gil . Oral administration of a tumeric extract inhibits LDL oxidation and has hypocholesterolemic effect in rabbits with experimental atherosclerosis. Atherosclerosis 147: 371–378, 1999.
A.C. Beynen , A.G. Lemmens , M.B. Katan , J.J. De. Bruijne , and L.F.V.a.n. Zutphen . Cholesterol metabolism and esterases in four strains of rats with different cholesterolemic responses to a high-cholesterol, high-cholate diet. Comp Biochem Physiol B 87: 41–48, 1987.
Y. Sakuma , H. Hagihara , A. Nagayoshi , K. Ohne , S. Mutoh , Y. Ito , K. Nakahara , Y. Notsu , and M. Okuhara . Effects of FRI45237, an aryl-CoA: cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats. Life Sci 60: 351–356, 1997.
M.G. Soret , M.C. Blanks , G.C. Gerritsen , C.E. Day , and E.M. Block . Diet induced hypercholesterolemia in the diabetic and non-diabetic Chinese hamster. Adv Exp Med Biol 67: 329–343, 1976.
J. Beitz , and H.J. Mest . A new derivative of trapidil (AR 12456) as a potential new antiatherosclerotic drug. Cardiovasc Drug Rev 9: 385–397, 1991.
P.A. Beere , S. Glagov , and C.H.K. Zarins . Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Atherioscl Thrombos 12: 1245–1253, 1992.
T.T.C. Yang and M.W.L. Koo . Hypocholesterolemic effects of Chinese tea. Pharmacol Res 35: 505–512, 1997.
T. Ogishima and K. Okuda . An improved method for assay of cholesterol 7a-hydroxylase activity. Anal Biochem 158: 228–232, 1986.
J.H. Sung , S.J. Choi , S.W. Lee , K.H. Park , and T.W. Moon . Isoflavones found in Korean soybean paste as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Biosci Biotechnol Biochem 68: 1051–1058, 2004.
S. Nagaoka , K. Miwa , M. Eto , Y. Kuzuya , G. Hori , and K. Yamamoto . Soy protein peptic hydrolysate with bound phospholipids decreases micellar solubility and cholesterol absorption in rats and Caco-2 cells. J Nutr 129: 1725–1730, 1999.
T.M. de Kok , S.G. van Breda , and M.M. Manson . Mechanisms of combined action of different chemopreventive dietary compounds. Eur J Nutr 47: 51–59, 2008.
H. Meisel . Biochemical properties of peptides encrypted in bovine milk proteins. Curr Med Chem 12: 1905–1919, 2005.
C.M. Holst and S.M. Oredsson . Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines. Toxicol in Vitro 19: 379–387, 2005.
C. Freiburghaus , B. Janicke , H. Lindmark-Mansson , S.M. Oredsson , and M.A. Paulsson . Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer cell line. J Dairy Sci 92: 2477–2484, 2009.
C.C. Hsieh , B. Hernández-Ledesma , and B.O. de Lumen . Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem-Biol Inter 186, 127–134, 2010.
J.H. Wong and T.B. Ng . Lunatusin, a trypsin-stable antimicrobial peptide from lima beans (Phaseolus lunatus L.). Peptides 26, 2086–2092, 2005.
M. Kampa , E. Bakogeorgou , A. Hatzoglou , A. Damianaki , P.M. Martin , and E. Castanas . Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 335: 255–265, 1997.
R. Hartmann , S. Gunther , D. Martin , H. Meisel , A.K. Pentzien , E. Schlimme , and N. Scholz . Cytochemical model systems for the detection and characterization of potentially bioactive milk components. Kieler Milchwirtschaftliche Forchungsberichte 52: 61–85, 2000.
J.A. Milner . Molecular targets for bioactive food components. J Nutr 134: 2492S–2498S, 2004.
P. Trayhurn . Proteomics and nutrition—A science for the first decade of the new millennium. Br J Nutr 83: 1–2, 2000.
R.E. Banks , M.J. Dunn , D.F. Hochstrasser , J.C. Sanchez , W. Blackstock , D.J. Pappin , and P.J. Selby . Proteomics: New perspectives, new biomedical opportunities. Lancet 356: 1749–1756, 2000.
W.C. Yang , J. Mathew , A. Velcich , W. Edelmann , R. Kucherlapati , M. Lipkin , K. Yang , and L.H. Augenlicht . Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 61: 565–569, 2001.
X. Yang , S.M. Edgerton , S.D. Kosanke , T.L. Mason , K.M. Alvarez , N. Liu , R.T. Chatterton et al. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-cerbB-2 transgenic mice. Cancer Res 63: 2425–2433, 2003.
L.Y. Fong , H. Ishii , V.T. Nguyen , A. Vecchione , J.L. Farber , C.M. Croce , and K. Huebner . deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. Cancer Res 63: 186–195, 2003.
A.R. Kennedy , P.C. Billings , P.A. Maki , and P. Newberne . Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 19: 191–202, 1993.
H. Witschi and A.R. Kennedy . Modulation of lung tumor development in mice with the soybean-derived Bowman–Birk protease inhibitor. Carcinogenesis 10: 2275–2277, 1989.
E. von Hofe , P.M. Newberne , and A.R. Kennedy . Inhibition of N-nitrosomethylbenzylamine induced esophageal neoplasms by the Bowman–Birk protease inhibitor. Carcinogenesis 12: 2147–2150, 1991.
S.M. Evans , T. Van Winkle , B.F. Szuhaj , K.E. Michel , and A.R. Kennedy . Protection against metastasis of radiation induced thymic lymphosarcoma and weight loss in C57Bl/6NCr1BR mice by an autoclave resistant factor present in soybeans. Rad Res 132: 259–262, 1992.
N. Sakurai , K. Suzuki , Y. Sano , T. Saito , H. Yoshimura , Y. Nishimura , T. Yano , Y. Sadzuka , and R. Asano . Effects of a single-dose administration of Bowman–Birk inhibitor concentrate on anti-proliferation and inhabitation of metastasis in M5076 ovarian sarcoma-bearing mice. Mol Med Rep 1: 903–907, 2008.
X.S. Wan , J.H. Ware , and L.L. Zhang . Treatment with soybean-derived Bowman–Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice. Prostate 41: 243–252, 1999.
H. Kobayashi , Y. Fukuda , R. Yoshida , R.Y. Kanada , S. Nishiyama , M. Suzuki , N. Kanayama , and T. Terao . Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model. Int J Cancer 112: 519–524, 2004.
C.C. Hsieh , B. Hernández-Ledesma , and B.O. de Lumen . Complementary roles in cancer prevention: Protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS ONE 5: e88-90, 2010.
J.N. Losso . The biochemical and functional food properties of the Bowman–Birk inhibitor. Crit Rev Food Sci Nutr 48: 94–118, 2008.
M. Foltz , P. Ansems , J. Schwarz , M.C. Tasker , A. Lourbakos , and C.C. Gerhardt . Protein hydrolysates induce CCK release from enteroendocrine cells and act as partial agonists of the CCK1 receptor. J Agric Food Chem 56: 837–843, 2008.
M. Shimizu and D.O. Son . Food-derived peptides and intestinal functions. Curr Pharm Design 13: 885–895, 2007.
D. Young and Y. Mine . Functional bioactive proteins and peptides in nutrigenomics. In Y. Mine , K. Miyashita , and F. Shahidi (eds), Nutrigenomics and Proteomics in Health and Disease. Food Factors and Gene Interactions, Oxford, UK: Wiley–Blackwell, 2009, pp. 129–144.
I. López-Expósito , L. Amigo , and I. Recio . Identification of the initial binding sites of alpha(s2)casein f(183-207) and effect on bacterial membranes and cell morphology. BBA Biomembranes 1778: 2444, 2008.
C.C. Hsieh , B. Hernández-Ledesma , and B.O. de Lumen . Cell proliferation inhibitory and apoptosis-inducing properties of anacardic acid and lunasin in human breast cancer MDA-MB-231 cells. Food Chem 125: 630, 2011.
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.